<SEC-DOCUMENT>0001193125-18-120604.txt : 20180418
<SEC-HEADER>0001193125-18-120604.hdr.sgml : 20180418
<ACCEPTANCE-DATETIME>20180418120133
ACCESSION NUMBER:		0001193125-18-120604
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20180531
FILED AS OF DATE:		20180418
DATE AS OF CHANGE:		20180418
EFFECTIVENESS DATE:		20180418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		18760614

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d521080ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Rule <FONT
STYLE="white-space:nowrap">14a-101)</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A INFORMATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Proxy Statement Pursuant to Section 14(a) of the </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Securities Exchange Act of 1934 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Filed&nbsp;by&nbsp;the&nbsp;Registrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Filed&nbsp;by&nbsp;a&nbsp;Party&nbsp;other&nbsp;than&nbsp;the&nbsp;Registrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preliminary Proxy Statement </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Definitive Proxy Statement </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Definitive Additional Materials </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Soliciting Material Pursuant to &#167; <FONT STYLE="white-space:nowrap">240.14a-12</FONT>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA, INC. </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name of Registrant as Specified in
Its Charter) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Name of Person(s) Filing Proxy Statement if Other Than the Registrant) </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Payment of Filing Fee (Check the appropriate box) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">No fee required. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT
STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>1.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Title of each class of securities to which transaction applies: </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>2.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Aggregate number of securities to which transaction applies: </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>3.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT
STYLE="white-space:nowrap">0-11</FONT> (Set forth the amount on which the filing fee is calculated and state how it was determined): </P></TD></TR></TABLE> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>4.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Proposed maximum aggregate value of transaction: </P></TD></TR></TABLE>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>5.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Total fee paid: </P></TD></TR></TABLE>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fee paid previously with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Check box if any part of the fee is offset as provided by Exchange Act Rule
<FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>6.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Amount Previously Paid: </P></TD></TR></TABLE>
<P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>7.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Form, Schedule or Registration Statement No.: </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>8.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Filing Party: </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%" VALIGN="top" ALIGN="left"><B>9.</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B></B>Date Filed: </P></TD></TR></TABLE>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11080 CirclePoint Road, Suite 140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Westminster, Colorado 80020 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">April&nbsp;18, 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholders of ARCA
biopharma, Inc.: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) of ARCA
biopharma, Inc., a Delaware corporation (the &#147;Company&#148; or &#147;ARCA&#148;). The meeting will be held on Thursday, May&nbsp;31, 2018, at 9:00 a.m. local time at the Renaissance Boulder Flatiron Hotel, 500 Flatiron Blvd, Broomfield, CO
80021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The matters scheduled to be considered at the meeting are (1)&nbsp;to elect the nominees of the Company&#146;s Board of Directors
(the &#147;Board of Directors&#148;), Dr.&nbsp;Raymond&nbsp;L. Woosley and Mr.&nbsp;Daniel&nbsp;J. Mitchell, to the Board of Directors to hold office until the 2021 Annual Meeting of Stockholders, (2)&nbsp;to ratify the selection by the Audit
Committee of the Board of Directors (the &#147;Audit Committee&#148;) of KPMG LLP (&#147;KPMG&#148;) as the independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31, 2018, and (3)&nbsp;to conduct any
other business properly brought before the meeting. These items of business are more fully described in this proxy statement that you are encouraged to read in its entirety. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">In accordance with the Securities and Exchange Commission (&#147;SEC&#148;) rule (&#147;Notice and Access Rule&#148;) that allows companies to
furnish their proxy materials (including the form of proxy, this proxy statement and our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, filed with the SEC on March&nbsp;22, 2018)
over the Internet, we intend to send a Notice of Internet Availability of Proxy Materials (&#147;Notice&#148;) on or about April&nbsp;20,&nbsp;2018 to our stockholders of record as of April&nbsp;2, 2018. We will also provide access to our proxy
materials over the Internet by April&nbsp;20, 2018. As a result of the Notice and Access Rule, all stockholders receiving the Notice have the ability to access the proxy materials over the Internet and request to receive a paper copy of the proxy
materials by mail. Instructions on how to access the proxy materials over the Internet or to request a paper copy may be found on the Notice. In addition, the Notice contains instructions on how stockholders may request to receive proxy materials
electronically by <FONT STYLE="white-space:nowrap">e-mail.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">All stockholders are cordially invited to attend the Annual Meeting in
person. Whether or not you expect to attend the Annual Meeting, please vote, as instructed in the Notice of Internet Availability of Proxy Materials, via the Internet or the telephone, as promptly as possible in order to ensure your representation
at the Annual Meeting. Alternatively, you may follow the procedures outlined in the Notice of Internet Availability of Proxy Materials to request a paper proxy card to submit your vote by mail. Even if you have voted by proxy, you may still vote in
person if you attend the Annual Meeting. Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely,</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g521080snap1.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>CHRISTOPHER OZEROFF</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Secretary, Senior Vice President and General Counsel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11080 CirclePoint Road, Suite 140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Westminster, Colorado 80020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON MAY&nbsp;31, 2018 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">Notice is hereby given that the Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) of ARCA biopharma, Inc., a Delaware
corporation (the &#147;Company&#148; or &#147;ARCA&#148;) will be held on Thursday, May&nbsp;31, 2018, at 9:00 a.m. local time at the Renaissance Boulder Flatiron Hotel, 500 Flatiron Blvd, Broomfield, CO 80021, for the following purposes: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To elect the Board of Directors&#146; nominees,
Dr.&nbsp;Raymond&nbsp;L. Woosley and Dan J. Mitchell, to the Board of Directors to hold office until the 2021 Annual Meeting of Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To ratify the selection by the Audit Committee of the Board of
Directors of KPMG LLP as independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To conduct any other business properly brought before the meeting.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">These items of business are more fully described in the proxy statement accompanying this Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman">The record date for the Annual Meeting is April&nbsp;2, 2018. Only stockholders of record at the close of business on that date may vote at
the meeting or any adjournment thereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By Order of the Board of Directors:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g521080snap1.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>CHRISTOPHER OZEROFF</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Secretary, Senior Vice President and General Counsel&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>W<SMALL>ESTMINSTER</SMALL>, CO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>PRIL</SMALL>&nbsp;18, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>Pursuant to the Internet proxy rules promulgated by the Securities and Exchange Commission, the Company has elected to provide access to
its proxy materials over the Internet. Accordingly, stockholders of record at the close of business on April&nbsp;2, 2018, will receive a Notice of Internet Availability of Proxy Materials and may vote at the Annual Meeting and any adjournment or
postponement thereof. The Company expects to mail the Notice of Internet Availability of Proxy Materials on or about April&nbsp;20, 2018.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:7%; font-size:10pt; font-family:Times New Roman"><B>All stockholders are cordially invited to attend the Annual Meeting in person. Whether or not you expect to attend the Annual Meeting,
please vote, as instructed in the Notice of Internet Availability of Proxy Materials, via the Internet or the telephone, as promptly as possible in order to ensure your representation at the annual meeting. Alternatively, you may follow the
procedures outlined in the Notice of Internet Availability of Proxy Materials to request a paper proxy card to submit your vote by mail. Even if you have voted by proxy, you may still vote in person if you attend the Annual Meeting. Please note,
however, that if your shares are held of record by a broker, bank or other agent and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name from that record holder.</B> </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11080 CirclePoint Road, Suite 140 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Westminster, Colorado 80020 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE
2018 ANNUAL MEETING OF STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAY&nbsp;31, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This proxy statement (this &#147;Proxy Statement&#148;) is being furnished to holders of ARCA biopharma, Inc. (sometimes referred to as the
&#147;Company,&#148; &#147;ARCA,&#148; &#147;we,&#148; &#147;us,&#148; and &#147;our&#148;) common stock, par value $0.001 per share (the &#147;Common Stock&#148;). Proxies are being solicited on behalf of the Board of Directors of ARCA to be used
at the Annual Meeting of Stockholders (the &#147;Annual Meeting&#148;) to be held on Thursday, May&nbsp;31, 2018, at 9:00 a.m. local time at the Renaissance Boulder Flatiron Hotel, 500 Flatiron Boulevard, Broomfield, CO 80021, and at any
postponement or adjournment thereof, for the purposes set forth in the Notice of Annual Meeting of Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ARCA is using the
Securities and Exchange Commission (the &#147;SEC&#148;) rule that allows companies to furnish their proxy materials over the Internet. As a result, we intend to mail to our stockholders a Notice of Internet Availability of Proxy Materials (the
&#147;Notice&#148;) instead of a paper copy of the proxy materials (including the form of proxy, this Proxy Statement and our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, filed
with the SEC on March&nbsp;22, 2018 (the &#147;2017 Annual Report&#148;), collectively, the &#147;Proxy Materials&#148;) on or about April&nbsp;20, 2018. We will also provide access to our Proxy Materials over the Internet by April&nbsp;20, 2018. By
furnishing the Notice to our stockholders of record, you <B><I><U>will not</U></I></B> receive a printed copy of the Proxy Materials in the mail. Instead, the Notice instructs you on how to access and review all of the important information
contained in the Proxy Statement and Annual Report electronically or to receive a printed version in the mail. The Notice also instructs you on how you may submit your proxy over the Internet, by toll-free number or in person at the Annual Meeting.
After receiving the Notice, all stockholders can access the Proxy Materials over the Internet and request to receive a paper copy of the Proxy Materials by mail. Instructions on how to access the Proxy Materials over the Internet or to request a
paper copy may be found on the Notice. In addition, the Notice contains instructions on how stockholders may request to receive Proxy Materials electronically by <FONT STYLE="white-space:nowrap">e-mail.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All stockholders may view and print ARCA&#146;s proxy statement and the 2017 Annual Report, which are available at www.arcabio.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why did I receive a notice regarding the availability of the Proxy Materials on the Internet? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As described above, pursuant to rules adopted by the SEC, we have elected to provide access to the Proxy Materials over the Internet.
Accordingly, on or about April&nbsp;20, 2018, we expect to send the Notice to ARCA&#146;s stockholders of record. The Board of Directors is soliciting your proxy to vote at the Annual Meeting. All stockholders can access the Proxy Materials on the
website referred to in the Notice or request to receive a printed or electronic set of the Proxy Materials. Instructions on how to access the Proxy Materials over the Internet or to request a printed copy may be found in the Notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I attend the Annual Meeting? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
meeting will be held on Thursday, May&nbsp;31, 2018, at 9:00 a.m. local time at the Renaissance Boulder Flatiron Hotel, 500&nbsp;Flatiron Blvd, Broomfield, CO 80021. Directions to the Annual Meeting may be found at<B> </B>www.arcabio.com.
Information on how to vote in person at the Annual Meeting is discussed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who can vote at the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Only stockholders of record at the close of business on April&nbsp;2, 2018, will be entitled to vote at the Annual Meeting. On this record
date, there were 13,914,320 shares of Common Stock outstanding and entitled to vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your
Name</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If, on April&nbsp;2, 2018, your shares of our Common Stock were registered directly in your name with ARCA&#146;s transfer
agent, Computershare Trust Company N.A., then you are a stockholder of record. As a stockholder of record, you may vote in person at the meeting or vote by proxy. Whether or not you plan to attend the meeting, we urge you to vote by proxy over the
telephone or on the Internet (as instructed below) or return the proxy card we may mail to you to ensure your vote is counted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of a Broker or Bank</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If, on April&nbsp;2, 2018, your shares of our Common Stock were held, not in your name, but rather in an account at a brokerage firm, bank,
dealer, or other similar organization, then you are the beneficial owner of shares held in &#147;street name&#148; and the Notice is being forwarded to you by that organization. The organization holding your account is considered to be the
stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting.
However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you request and obtain a valid proxy from your broker or other agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What am I voting on? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are two
matters scheduled for a vote: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT> &nbsp;&nbsp;Election of two directors; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:-3%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT> &nbsp;&nbsp;Ratification of selection by the Audit Committee (the
&#147;Audit Committee&#148;) of the Board of Directors of KPMG LLP (&#147;KPMG&#148;) as independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31, 2018; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if another matter is properly brought before the meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are
properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I vote? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You may either vote
&#147;For&#148; each nominee to the Board of Directors or you may &#147;Withhold&#148; your vote for each nominee. For all other matters to be voted on, you may vote &#147;For&#148; or &#147;Against&#148; or abstain from voting. The procedures for
voting are fairly simple: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you are a stockholder of record, you may vote in person at the Annual Meeting, vote by proxy over the telephone, vote by proxy through the
Internet or vote by proxy using a proxy card that you may request or that we may elect to deliver at a later time. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the
meeting and vote in person even if you have already voted by proxy. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">To vote using the proxy card, simply complete, sign and date the proxy card that may be delivered<B> </B>and return it promptly in the envelope provided. If you return your signed proxy card to us before the Annual
Meeting, we will vote your shares as you direct. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">To vote over the telephone, dial toll-free <B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-652-VOTE</FONT></FONT></FONT> (8683)</B>&nbsp;using a touch-tone
phone and follow the recorded instructions. You will be asked to provide the company number and control number from the Notice. Your vote must be received by 1:00 a.m. Mountain Time on May&nbsp;31, 2018, to be counted. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">To vote through the Internet, go to <B>http://www.investorvote.com/ABIO</B> to complete an electronic proxy card. You will be asked to provide the company number and control number from the Notice. Your vote must be
received by 1:00 a.m. Mountain Time on May&nbsp;31, 2018, to be counted. </TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owner: Shares Registered in the Name of Broker or
Bank</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares registered in the name of your broker, bank, or other agent, you should have received a
Notice containing voting instructions<B> </B>from that organization rather than from ARCA. Simply follow the voting instructions in the Notice<B> </B>to ensure that your vote is counted. To vote in person at the Annual Meeting, you must obtain a
valid proxy from your broker, bank, or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>We provide Internet proxy voting to allow you to vote your shares online, with procedures designed to ensure the authenticity and
correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your access to the Internet, such as usage charges from Internet access providers and telephone companies.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes do I have? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On each
matter to be voted upon, you have one vote for each share of Common Stock you owned as of April&nbsp;2, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I return a proxy card or
otherwise vote but do not make specific choices? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you return a signed and dated proxy card or otherwise vote without marking voting
selections, your shares will be voted, as applicable, &#147;For&#148; the election of each nominee for director and &#147;For&#148; Proposal 2. If any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other matter is properly presented at the meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is paying for this proxy solicitation? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will pay for the entire cost of soliciting proxies. In addition to these proxy materials, the directors and employees may also solicit
proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of
forwarding proxy materials to beneficial owners.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What does it mean if I receive more than one Notice? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting
instructions on each Notice to ensure that all your shares are voted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I change my vote after submitting my proxy? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your shares, you may revoke
your proxy in any one of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">You may submit another properly completed proxy card with a later date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">You may grant a subsequent proxy by telephone or through the Internet. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">You may send a timely written notice that you are revoking your proxy to ARCA&#146;s Secretary at 11080 CirclePoint Road, Suite 140, Westminster, Colorado, 80020.<B> </B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">You may attend the Annual Meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Your most current proxy card or telephone or Internet proxy is the one that is counted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>When are stockholder proposals due for next year&#146;s annual meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To be considered for inclusion in next year&#146;s proxy materials, your proposal must be submitted in writing by December&nbsp;19, 2018, to
ARCA&#146;s Secretary at 11080 CirclePoint Road, Suite 140, Westminster, Colorado, 80020. If you wish to submit a proposal that is not to be included in next year&#146;s proxy materials or nominate a director, you must do so by no earlier than
March&nbsp;2, 2019, and no later than April&nbsp;1, 2019. You are also advised to review the Company&#146;s Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How are votes counted? </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Votes will be
counted by the inspector of election appointed for the meeting. For Proposal 1, to elect new directors, votes &#147;For&#148; and &#147;Withhold&#148; will be counted. For Proposal 2, votes &#147;For&#148; and &#147;Against&#148;, abstentions and
broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted. Abstentions will be counted towards the vote total for Proposal 2, and will have the same effect as &#147;Against&#148; votes. Broker
<FONT STYLE="white-space:nowrap">non-votes</FONT> have no effect and will not be counted towards the vote total for any proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What are
&#147;broker <FONT STYLE="white-space:nowrap">non-votes&#148;?</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> occur
when a beneficial owner of shares held in &#147;street name&#148; does not give instructions to the broker or nominee holding the shares<B> </B>as to how to vote. Generally, if shares are held in street name, the beneficial owner of the shares is
entitled to give voting instructions to the broker or nominee holding the shares. If the beneficial owner does not provide voting instructions, the broker or nominee<B> </B>can still vote the shares with respect to matters that are considered to be
&#147;routine,&#148; but not with respect to <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters. Under the rules and interpretations of the New York Stock Exchange, <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT>
matters are matters that may substantially affect </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the rights or privileges of stockholders, such as mergers, stockholder proposals and elections of directors, even if not contested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes are needed to approve each proposal? </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Proposal No.&nbsp;1, for the election of directors. For this proposal, the two nominees receiving the most &#147;For&#148; votes (from the holders of votes of shares present in person or represented by proxy and
entitled to vote on the election of directors) will be elected. Only votes &#147;For&#148; or &#147;Withheld&#148; votes will affect the outcome. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#216;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Proposal No.&nbsp;2, to ratify the selection of KPMG as the Company&#146;s independent registered public accounting firm for fiscal year 2018. This proposal must receive &#147;For&#148; votes from the holders of a<B>
</B>majority of shares present and entitled to vote either in person or by proxy. If you &#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have
no effect. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the quorum requirement? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding a majority of the outstanding
shares of Common Stock entitled to vote are present at the meeting in person or represented by proxy. On the record date, April&nbsp;2, 2018, there were 13,914,320 shares of Common Stock outstanding and entitled to vote. Thus, the holders of
6,957,161 shares of Common Stock must be present in person or represented by proxy at the meeting to have a quorum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Your shares will be
counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT>
will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present at the meeting in person or represented by proxy may adjourn the meeting to another date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I find out the results of the voting at the Annual Meeting? </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a current report on
Form <FONT STYLE="white-space:nowrap">8-K</FONT> that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us in time to file a <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT>
within four business days after the meeting, we intend to file a <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> to publish preliminary results and, within four business days after the final results are known to us, file an additional <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> to publish the final results. </P> <P STYLE="margin-top:42pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NO PERSON IS AUTHORIZED TO GIVE ANY INFORMATION OR TO
MAKE ANY REPRESENTATION OTHER THAN THOSE CONTAINED IN THIS PROXY STATEMENT, AND, IF GIVEN OR MADE, SUCH INFORMATION MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED. THE DELIVERY OF THIS PROXY STATEMENT SHALL, UNDER NO CIRCUMSTANCES, CREATE ANY
IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF ARCA SINCE THE DATE OF THIS PROXY STATEMENT.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>LECTION</SMALL> <SMALL>OF</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Amended and Restated Certificate of Incorporation provides that the Board of Directors is divided into three classes to
provide for staggered terms and that each director will serve for a term of three years or less, depending on the class to which the Board of Directors has assigned a director not previously elected by the stockholders. There are currently no
vacancies on the Board of Directors. Vacancies on the Board of Directors may be filled only by persons elected by a majority of the remaining directors. A director elected by the Board of Directors to fill a vacancy in a class, including vacancies
created by an increase in the number of directors,<B> </B>shall serve for the remainder of the full term of that class and until the director&#146;s successor is duly elected and qualified.<B> </B>The Company may reduce or increase the size of the
Board of Directors by resolution adopted by the affirmative vote of a majority of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are currently two Class&nbsp;III
directors whose terms expire at the annual stockholders&#146; meeting in 2018, two Class&nbsp;I directors whose terms expire at the annual stockholders&#146; meeting in 2019 and two Class&nbsp;II directors whose terms expire at the annual meeting in
2020. The Board of Directors has nominated two Class&nbsp;III directors, Dr.&nbsp;Raymond L. Woosley and Dan J. Mitchell, for election to the Board of Directors, for a three-year term ending on the date of the annual meeting in 2021 or until their
successors are duly elected and qualified or appointed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If elected at the Annual Meeting, Dr.&nbsp;Woosley and Mr.&nbsp;Mitchell would
serve until the 2021 annual meeting and until their successors have been duly elected and qualified, or, if sooner, until the director&#146;s death, resignation or removal. It is the Company&#146;s policy to encourage directors and nominees for
director to attend the Annual Meeting. Four of the Company&#146;s directors then on the Board of Directors attended the 2017 Annual Meeting of Stockholders in person, and one attended by telephone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on
the election of directors. The two nominees receiving the highest number of affirmative votes will be elected. Each person nominated for election has agreed to serve if elected. The Company&#146;s management has no reason to believe that either
nominee will be unable to serve. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Qualifications and Diversity </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The below paragraphs provide information, as of the date of this proxy statement, about each nominee and current members of the Board of
Directors, including age, all positions currently held, principal occupation and business experience for the past five years. In addition to the information presented regarding each nominee&#146;s specific experience, qualifications, attributes and
skills that led the Board of Directors to conclude that such director or nominee should be able to serve as a director, the Board of Directors also believes that all of the directors and nominees have a reputation of integrity, honesty and adherence
to high ethical standards. They each have demonstrated business acumen and an ability to exercise sound judgment as well as a commitment to service to ARCA and the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee of the Board of Directors (the &#147;Nominating and Corporate Governance Committee&#148;)
considers diversity in the director identification and nomination process. The Nominating and Corporate Governance Committee seeks nominees with a broad diversity of experience, professions, skills, geographic representation and backgrounds. The
Nominating and Corporate Governance Committee does not assign specific weights to particular criteria and no particular criterion is necessarily applicable to all prospective nominees. ARCA believes that the backgrounds and qualifications of the
directors, considered as a group, should provide a significant composite mix of experience, knowledge and abilities that will allow the Board of Directors to fulfill its responsibilities. Nominees are not discriminated against on the basis of race,
religion, national origin, sexual orientation, disability or any other basis proscribed by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N<SMALL>OMINEE</SMALL> <SMALL>FOR</SMALL> E<SMALL>LECTION</SMALL> <SMALL>FOR</SMALL>
<SMALL>A</SMALL> T<SMALL>HREE</SMALL>-<SMALL>YEAR</SMALL> T<SMALL>ERM</SMALL> E<SMALL>XPIRING</SMALL> <SMALL>AT</SMALL> <SMALL>THE</SMALL> 2020 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> N<SMALL>AMED</SMALL>
N<SMALL>OMINEES</SMALL>. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Raymond L. Woosley, M.D., Ph.D. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Woosley, age 75, was appointed to the Board of Directors in July 2013.&nbsp;Dr.&nbsp;Woosley is currently Professor of Medicine and <FONT
STYLE="white-space:nowrap">Co-Director</FONT> of the Division for Data Analytics and Decision Support in the Department of Medicine of the University of Arizona, College of Medicine in Phoenix.&nbsp;Since 2012, Dr.&nbsp;Woosley has served as the
Director of the Arizona Center for Education and Research on Therapeutics (AzCERT), an independent, nonprofit research and education organization.&nbsp;He is also President Emeritus of the Critical Path Institute
<FONT STYLE="white-space:nowrap">(C-Path),</FONT> a <FONT STYLE="white-space:nowrap">non-profit,</FONT> public-private partnership with the U.S. Food and Drug Administration, of which he was a founder in November 2004, and where he served as
President, Chief Executive Officer and Chairman of the board of directors from 2005 to 2011.&nbsp;Since 2001, Dr.&nbsp;Woosley has also been a Professor of Medicine and Pharmacology at The University of Arizona Health Sciences Center in Tucson, AZ,
and, since 2012, Professor Emeritus, where he was also Vice President for Health Sciences from 2001 to 2005, and Dean of the College of Medicine from 2001 to 2002.&nbsp;From 1988 to 2001, Dr.&nbsp;Woosley was a professor of medicine at the
Georgetown University School of Medicine, where he was also Director of the Institute of Cardiovascular Sciences from 1994 to 2000, and Division Chief, Clinical Pharmacology, in the Department of Medicine from 1988 to 1994.&nbsp;From 1976 to 1988 he
was a member of the faculty of Vanderbilt University where he rose to the rank of Professor of Medicine and Pharmacology and Associate Director of the NIH funded General Clinical Research Center.&nbsp;Dr.&nbsp;Woosley earned his Ph.D. in
Pharmacology from the University of Louisville and his M.D. from the University of Miami.&nbsp;Dr.&nbsp;Woosley&#146;s research has been published in over 312 peer-reviewed publications and 52 book chapters.&nbsp;We believe Dr.&nbsp;Woosley is an
appropriate member of the Board of Directors, given his expertise and experience in cardiovascular medicine and clinical pharmacology, arrhythmia therapeutics, pharmacogenetic drug development and therapeutic regulatory science. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dan J. Mitchell </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Mitchell, age
61, was appointed to the Board of Directors in February 2014. He founded, and is a manager of Sequel Venture Partners, L.L.C., a venture capital firm formed in January 1997. Prior to founding Sequel Venture Partners, Mr.&nbsp;Mitchell was a founder
of Capital Health Venture Partners, a health care focused venture capital firm, where he was a General Partner from October 1986 until 2006, and he was in the Venture Capital Division of the Trust Department of the First National Bank of Chicago
from 1983 to 1985. He currently serves on the board of directors of several private companies. Mr.&nbsp;Mitchell holds a B.S. from the University of Illinois and an M.B.A. from the University of California at Berkeley. We believe Mr.&nbsp;Mitchell
is an appropriate member of the Board of Directors given his expertise and experience in the pharmaceutical industry, pharmaceutical development, and in corporate finance and governance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL> O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL> 2019
A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Linda Grais, M.D. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Grais, age 61, has served as a member of the Board of Directors since May 2007. Dr.&nbsp;Grais has been a director of Ocera
Therapeutics, Inc., a public biopharmaceutical company, since January 2008 and became President and Chief Executive Officer of Ocera in June 2012. Dr.&nbsp;Grais served as a Managing Member at InterWest Partners, a venture capital firm from has
served as a member of the Board of Directors since May 2007. Dr.&nbsp;Grais has been a director of Ocera Therapeutics, Inc., a public biopharmaceutical company, since January 2008 and became President and Chief Executive Officer of Ocera in June
2012, and served in that role until Ocera&#146;s acquisition by Mallinckrodt Pharmaceuticals in December 2017. Dr.&nbsp;Grais served as a Managing Member at InterWest Partners, a venture capital firm from May 2005 until February 2011. From July 1998
to July 2003, Dr.&nbsp;Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich&nbsp;&amp; Rosati, where she practiced in such
areas as venture financings, public offerings and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
strategic partnerships. Before practicing law, Dr.&nbsp;Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco.
Dr.&nbsp;Grais received a B.A. from Yale University, magna cum laude, and Phi Beta Kappa, an M.D. from Yale Medical School and a J.D. from Stanford Law School. Since September 2015, Dr.&nbsp;Grais has served on the board of PRA Health Sciences, a
public contract research organization. We believe Dr.&nbsp;Grais is an appropriate member of the Board of Directors because of her diverse training and experience as both a medical doctor and a lawyer, her experience as a founder and senior
executive of a pharmaceutical company, and her experience as an investor in new life sciences companies. She also has extensive experience with and knowledge of the Company&#146;s business from her service on the Board of Directors of the Company
since 2007. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anders Hove, M.D. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Hove, age 52, has served as a member of the Board of Directors since February 2017. Dr.&nbsp;Hove owns Acorn Capital Advisors and is
a managing partner at Majalin/Amzak Health, a partnership focusing on long-term investments in biotech, specialty pharma and medical device companies. Dr.&nbsp;Hove was most recently a general partner of Venrock Associates, a venture capital firm,
which he joined in January 2004 and remained at through December 2016. In 2008, Dr.&nbsp;Hove was a founder of Venrock Healthcare Capital Partners, Venrock&#146;s public funds focused on small capitalization biotech companies and late-stage private
companies. From 1996 to 2004, Dr.&nbsp;Hove was a fund manager at BB&nbsp;Biotech Fund, an investment firm, and from 2002 to 2003 he also served as Chief Executive Officer of Bellevue Asset Management, LLC, an investment company. Dr.&nbsp;Hove
previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy. Mr.&nbsp;Hove was a member of the boards of directors of Anacor Pharmaceuticals, a publicly traded pharmaceutical
company, from 2005 until its acquisition by Pfizer in June 2016, and Edge Therapeutics, a publicly traded biotechnology company, from 2015 to 2016. In addition, Dr.&nbsp;Hove is a member of the board of directors of MC2 Therapeutics. He received a
M.Sc. in Biotechnology Engineering from the Technical University of Denmark, an M.D. from the University of Copenhagen and an M.B.A. from the Institut Europ&eacute;en d&#146;Administration des Affaires. We believe Dr.&nbsp;Hove is an appropriate
member of the Company&#146;s Board of Directors, given his extensive training and experience as a medical doctor and masters of business administration, an executive in the pharmaceutical industry, and as an investor in biotechnology companies. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL> O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL> 2020
A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Michael R. Bristow, M.D., Ph.D. </B></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Bristow, age 73, was one of the founders of ARCA in September 2004, and has served as a Director since that time. Dr.&nbsp;Bristow
has also served as the Company&#146;s President and Chief Executive Officer since July 2009. Previously, Dr.&nbsp;Bristow served as the President and Chief Executive Officer of the Company from September 2004 to November 2006, and as the
Company&#146;s Chief Science and Medical Officer from November 2006 to July 2009. Dr.&nbsp;Bristow is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October
1991. Dr.&nbsp;Bristow was one of the founders of Myogen, Inc. and served as Myogen&#146;s Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen
by Gilead Sciences, Inc. in November 2006. We believe Dr.&nbsp;Bristow is an appropriate member of the Company&#146;s Board of Directors given his extensive experience and expertise as a cardiologist, medical researcher and drug developer in the
field of cardiovascular medicine, and heart failure specifically, and his experience as a founder and manager of cardiovascular-focused, public pharmaceutical company. Dr.&nbsp;Bristow also has extensive experience with, and knowledge of,
ARCA&#146;s business, as the founder and former Chief Science and Medical Officer of the Company, and the current President and Chief Executive Officer of ARCA, and as a member of the Board of Directors of ARCA since the founding of the Company.
Dr.&nbsp;Bristow holds a M.D. and Ph.D. from the University of Illinois. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Robert E. Conway </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Conway, age 64, was appointed to the Board of Directors in September 2013, and has served as the Chairman of our Board of Directors
since 2014. Mr.&nbsp;Conway served as the Chief Executive Officer and member of the board of directors of Array Biopharma, a publicly traded pharmaceutical company, from 1999 to 2012. Prior to joining Array, Mr.&nbsp;Conway was the Chief Operating
Officer and Executive Vice President of Hill Top Research, Inc., from 1996 to 1999. From 1979 until 1996, Mr.&nbsp;Conway held various executive positions for Corning Inc. including Corporate Vice President and General Manager of Corning Hazleton,
Inc., a contract research organization. From 2004 to 2013, he served on the board of directors of PRA International, Inc., which was a public company for a portion of his tenure there, from 2012 to the present, he has served on the board of
directors of eResearch Technology, Inc., a private company, and from 2015 to July 2017, he has served on the board of directors of Nivalis Therapeutics, Inc. a public, clinical stage pharmaceutical company. In July 2017, Nivalis Therapeutics, Inc.
combined with Alpine Immune Sciences,&nbsp;Inc., a public, clinical stage pharmaceutical company, and Mr.&nbsp;Conway continues to serve on the board of directors following such combination. Mr.&nbsp;Conway also serves as the Chairman of Wall Family
Enterprise, a leading library and educational supplies company. In addition, Mr.&nbsp;Conway is a member of the Strategic Advisory Committee of Genstar Capital, LLC and is a member of the board of directors of Bracket, Inc. Mr.&nbsp;Conway received
a B.S. in accounting from Marquette University in 1976. We believe Mr.&nbsp;Conway is an appropriate member of the Board of Directors given his experience and expertise in the pharmaceutical industry, in pharmaceutical development and clinical
trials, and in corporate finance, governance, accounting and public company compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>I<SMALL>NFORMATION</SMALL>
R<SMALL>EGARDING</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> <SMALL>AND</SMALL> C<SMALL>ORPORATE</SMALL> G<SMALL>OVERNANCE</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>NDEPENDENCE</SMALL> <SMALL>OF</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As required under the Nasdaq Stock Market (&#147;Nasdaq&#148;)<B> </B>listing standards, a majority of the members of a listed company&#146;s
board of directors must qualify as &#147;independent,&#148; as affirmatively determined by the board of directors. Our Board of Directors consults with the Company&#146;s counsel to ensure that the Board of Directors&#146; determinations are
consistent with relevant securities and other laws and regulations regarding the definition of &#147;independent,&#148; including those set forth in pertinent listing standards of the Nasdaq, as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of
his or her family members, and the Company, its senior management and its independent registered public accounting firm, the Board of Directors has affirmatively determined that the following five directors are independent directors within the
meaning of the applicable Nasdaq<B> </B>listing standards: Mr.&nbsp;Conway, Dr.&nbsp;Grais, Mr.&nbsp;Mitchell, Dr.&nbsp;Hove and Dr.&nbsp;Woosley. In making this determination, the Board of Directors found that none of the directors or nominees for
director had a material or other disqualifying relationship with the Company. Dr.&nbsp;Bristow, the Company&#146;s President and Chief Executive Officer, is not an<B> </B>independent director by virtue of his employment relationship with the
Company.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B<SMALL>OARD</SMALL> L<SMALL>EADERSHIP</SMALL> S<SMALL>TRUCTURE</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has structured its Board of Directors in a way that the Company believes effectively serves its objectives of corporate governance
and management oversight. The Company separates the roles of Chief Executive Officer and Chairman of the Board of Directors in recognition of the differences between the two roles. The Company believes that the Chief Executive Officer should be
responsible for the day to day leadership and performance of the Company, while the Chairman of the Board of Directors should work with the Chief Executive Officer and the rest of the Board of Directors to set the strategic direction for the Company
and provide guidance to, and oversight of the Chief Executive Officer. The Chairman also sets the agenda for meetings of the Board of Directors and presides over them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Conway, who is an independent director, was elected Chairman of the Board of Directors in 2014. In this capacity, Mr.&nbsp;Conway,
among other things, calls and presides over Board meetings, including meetings of the independent directors, and sets meeting agendas. In this role, Mr.&nbsp;Conway can effectively coordinate between the Board and management regarding risk
management issues and the implementation of appropriate responses, and can help ensure the effective independent functioning of the Board of Directors in its oversight responsibilities. Accordingly, the Chairman has substantial ability to shape the
work of the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>R<SMALL>OLE</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL>
D<SMALL>IRECTORS</SMALL> <SMALL>IN</SMALL> R<SMALL>ISK</SMALL> O<SMALL>VERSIGHT</SMALL> <SMALL>AND</SMALL> R<SMALL>ISK</SMALL> M<SMALL>ANAGEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">One of the Board of Directors&#146; key functions is informed oversight of the Company&#146;s risk management process. The Board of Directors
does not have a standing risk management committee, but rather administers this oversight function directly through the Board of Directors as a whole, as well as through various standing committees of the Board of Directors that address risks
inherent in their respective areas of oversight. In particular, while the Board of Directors is responsible for monitoring and assessing strategic risk exposure, the Audit Committee has the responsibility to consider and discuss the major financial
risk exposures and the steps management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The Audit Committee also monitors compliance
with legal and regulatory requirements, in addition to oversight of the performance of ARCA&#146;s accounting and financial reporting processes. The Nominating and Corporate Governance Committee monitors the effectiveness of the corporate governance
guidelines, including whether they are successful in preventing illegal or improper liability-creating conduct. The compensation committee of the Board of Directors (the &#147;Compensation Committee&#148;) assesses and monitors whether any
compensation policies and programs have the potential to encourage excessive risk-taking. The entire Board of Directors and its committees address risk management issues from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> and at least annually meet with the employees responsible for risk management in the committees&#146; respective areas of oversight. Both the Board of
Directors as a whole and the various standing committees receive periodic reports from the employees responsible for risk management, as well as incidental reports as matters may arise. It is the responsibility of the committee chairs to report
findings regarding material risk exposures to the Board of Directors as quickly as possible. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>M<SMALL>EETINGS</SMALL> <SMALL>OF</SMALL>
T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors met seven times during the
2017 fiscal year. The independent members of the Board of Directors met separately as a group at four of the board meetings in 2017. All members of the Board of Directors, other than Dr.&nbsp;Woosley, attended at least 75% of the meetings of the
Board of Directors and at least 75% the meeting of the committees of the Board of Directors of which each director was a member. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>NFORMATION</SMALL> R<SMALL>EGARDING</SMALL> C<SMALL>OMMITTEES</SMALL> <SMALL>OF</SMALL>
<SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors has three standing
committees:<B> </B>The Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. The following table provides membership and meeting information for the fiscal year ended December&nbsp;31, 2017, for each of
the committees of the Board of Directors: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD style="width:31pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:31pt"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD style="width:33pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:33pt"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD style="width:96pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:96pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Name</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;&nbsp;Compensation&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">&nbsp;Nominating&nbsp;and&nbsp;<BR>Corporate<BR>Governance</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Dr.&nbsp;Michael&nbsp;R. Bristow</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Dr.&nbsp;Linda Grais</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Dr.&nbsp;Raymond&nbsp;L. Woosley</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Mr.&nbsp;Robert&nbsp;E. Conway</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom">*</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Mr.&nbsp;Dan&nbsp;J. Mitchell</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Dr.&nbsp;Anders Hove</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">X</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Total meetings in fiscal 2017</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;*</TD>
<TD ALIGN="left" VALIGN="top">Committee Chairperson. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Hove was appointed to our Board of Directors in February
2017. Upon Dr.&nbsp;Hove&#146;s appointment to the Board of Directors, he joined our Nominating and Corporate Governance Committee. At the same time, Dr.&nbsp;Woosley left our Audit Committee, and Dr.&nbsp;Grais left our Nominating and Corporate
Governance Committee and joined our Audit Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Below is a description of each committee of the Board of Directors. Each of the
committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities.<B> </B>The Board of Directors has determined that each member of each committee meets the applicable Nasdaq
rules and regulations regarding &#147;independence&#148; and that each member is free of any relationship that would impair his or her individual exercise of independent judgment regarding the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Audit Committee </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Audit Committee was
established by the Board of Directors in accordance with Section&nbsp;3(a)(58)(A) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), to oversee the Company&#146;s corporate accounting and financial reporting processes
and audits of its financial statements. For this purpose, the Audit Committee performs several functions. The Audit Committee evaluates the performance of and assesses the qualifications of the independent registered public accounting firm;
determines and approves the engagement of the independent registered public accounting firm; determines whether to retain or terminate the existing independent registered public accounting firm or to appoint and engage a new independent registered
public accounting firm; reviews and approves the retention of the independent registered public accounting firm to perform any proposed permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services; monitors the rotation of partners of the
independent registered public accounting firm on the Company&#146;s audit engagement team as required by law; reviews and approves or rejects transactions between the company and any related persons; confers with management and the independent
registered public accounting firm regarding the effectiveness of internal controls over financial reporting; establishes procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company
regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; and meets to review the Company&#146;s annual
audited financial statements and quarterly financial statements with management and the independent registered public accounting firm, including a review of the Company&#146;s disclosures under the &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; discussion in its Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-QThe</FONT> Audit Committee is currently
composed of three<B> </B>directors: Mr.&nbsp;Conway (chair), Mr.&nbsp;Mitchell and Dr.&nbsp;Grais. The Audit Committee met five&nbsp;times during the fiscal year. The Board of Directors has adopted a written charter of the Audit Committee that is
available to stockholders<B> </B>on the Company&#146;s website at www.arcabio.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors reviews the Nasdaq listing standards definition of independence for audit
committee members on an annual basis and has determined that all members of the Audit Committee are independent (as independence is currently defined in Rule&nbsp;5605(c)(2)(A)(i) and (ii)&nbsp;of the Nasdaq listing standards).<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>The Board of Directors has also determined that Mr.&nbsp;Conway qualifies as an &#147;audit committee financial expert,&#148; as defined in applicable SEC rules.<B> </B>The Board of Directors made a
qualitative assessment of Mr.&nbsp;Conway&#146;s level of knowledge and experience based on several factors, including his prior experience, business acumen and independence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report of the Audit Committee of the Board of Directors<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Audit Committee has reviewed and discussed the audited financial statements for the fiscal year ended December&nbsp;31,&nbsp;2017, with
management of the Company. The Audit Committee has discussed with the independent registered public accounting firm the matters required to be discussed by Public Company Accounting Oversight Board (&#147;PCAOB&#148;) Auditing Standard
No.&nbsp;1301, Communications with Audit Committees. The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting firm required by applicable requirements of the PCAOB regarding the
independent registered public accounting firm&#146;s communications with the Audit Committee concerning independence, and has discussed with the independent registered public accounting firm the accounting firm&#146;s independence. Based on the
foregoing, the Audit Committee has recommended to the Board of Directors that the audited financial statements be included in the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="61%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Robert Conway</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Dan
Mitchell</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Linda Grais</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Compensation Committee is currently composed of three directors: Mr.&nbsp;Conway, Dr.&nbsp;Grais (chair) and Dr.&nbsp;Woosley. All members
of the Compensation Committee are independent, as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards. The Compensation Committee met one<B> </B>time during the fiscal year. The Compensation Committee has adopted a
written charter that is available to stockholders on the Company&#146;s website at www.arcabio.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the
Board of Directors acts on behalf of the Board of Directors to review, adopt and oversee the Company&#146;s compensation strategy, policies, plans and programs, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing succession planning for senior management of the Company, including a review of the performance and advancement potential of current and future senior management and succession plans for each and
recommending, as appropriate, the retention of potential succession candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assessing the overall compensation structure of the Company and evaluating and recommending changes to the Company&#146;s compensation philosophies and strategies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving performance-based compensation plans or programs, including establishing goals and targets, applicable to the Chief Executive Officer and other members of the management team; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering, reviewing, and approving all executive compensation programs or plans, and all of the Company&#146;s incentive compensation and stock plans and awards thereunder of the Company, including amendments to
the programs, plans or awards made thereunder; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The material in this report is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the Commission and is not to be incorporated by reference in any filing of the Company under the Securities Act of
1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing and approving the Report of the Compensation Committee to be included as part of the Company&#146;s annual meeting proxy statement, to the extent required. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Committee Processes and Procedures </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Typically, the Compensation Committee meets on a regular basis as it deems appropriate. The agenda for each meeting is usually developed by
the Chair of the Compensation Committee.<B></B>&nbsp;The Compensation Committee meets regularly in executive session. However, from time to time, various members of management and other employees as well as outside advisors or
consultants<B></B>&nbsp;may be invited by the Compensation Committee to make<B></B>&nbsp;presentations, to provide financial or other<B></B>&nbsp;background information or advice or to otherwise participate in Compensation Committee meetings. The
Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The Compensation Committee has the sole
authority to retain compensation consultants to assist in its evaluation of<B></B>&nbsp;executive<B></B>&nbsp;and director compensation, including the authority to approve the consultant&#146;s reasonable fees and other retention terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June 2013, the Company&#146;s Compensation Committee reviewed the Company&#146;s executive compensation considering general market
conditions in the life science industry. As part of this review process, the Compensation Committee identified a peer group of biotechnology companies that it viewed as having a similar profile to ARCA at that time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In setting 2017 base salary and cash bonus award amounts for the Company&#146;s named executive officers, the Compensation Committee
considered peer group data and factors specific to the Company, and targeted cash compensation to be consistent with these metrics. The Compensation Committee recommended, and the Board of Directors approved, a base salary of $295,359 for
Dr.&nbsp;Bristow, the Company&#146;s President and Chief Executive Officer, a base salary of $294,170 for Mr.&nbsp;Keuer, the Company&#146;s Chief Operating Officer, and a base salary of $288,683 for Mr.&nbsp;Ozeroff, the Company&#146;s Senior Vice
President and General Counsel, for the fiscal year ended December&nbsp;31, 2016. In early 2017, the Compensation Committee recommended and the Board of Directors approved cash bonuses based on previous performance for the Named Executive Officers
(as defined below), and also approved increases to Named Executive Officer salaries for the fiscal year 2017 as described in below under &#147;Executive Compensation.&#148; There were no changes to the Company&#146;s named executive officers&#146;
salaries for 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Historically, the Compensation Committee has made most of the significant adjustments to annual compensation,
determined bonus and equity awards and established new performance objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as
compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of the Company&#146;s compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various
meetings throughout the year. Generally, the Compensation Committee&#146;s process comprises two related elements:<B></B>&nbsp;the determination of compensation levels and the establishment of performance objectives for the current year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Compensation Committee reviews and approves the compensation of the Chief Executive Officer and the other executive officers of the
Company, including annual base salaries, annual and long-term incentive or bonus awards, employment agreements, and severance and change in control agreements/provisions, in each case as, when and if appropriate, and any special or supplemental
benefits. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee<B></B>&nbsp;by the Chief Executive Officer. The Compensation
Committee evaluates the performance of the Chief Executive Officer in light of Company and individual goals and objectives, and makes appropriate recommendations for improving performance. In performing the evaluation, the Chair of the Compensation
Committee may solicit comments from the <FONT STYLE="white-space:nowrap">other&nbsp;non-employee&nbsp;members</FONT> of the Board of Directors and lead the Board of Directors in an overall review of the Chief Executive Officer&#146;s performance in
an executive session <FONT STYLE="white-space:nowrap">of&nbsp;non-employee&nbsp;members</FONT> of the Board of Directors. If the compensation for the Chief Executive Officer or any other executive officer is governed by an employment agreement, the
Compensation Committee approves such employment agreement and any amendments thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For all executives as part of its deliberations, the Compensation Committee may review and
consider, as appropriate,<B></B>&nbsp;materials such as financial reports and projections, operational data, tax and accounting information, tally sheets that set forth the total compensation that may become payable to executives in various
hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Compensation Committee also considers the results of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">any&nbsp;&#147;say-on-pay&#148;&nbsp;vote</FONT></FONT> of the Company&#146;s stockholders with regard to the compensation of the Company&#146;s executive officers when making
compensation decisions. At the 2016 annual meeting of stockholders, the Company&#146;s stockholders approved, on an advisory basis, the compensation of the Company&#146;s named executive officers as described in the proxy statement for such annual
meeting. The Compensation Committee believes that this advisory vote supports that the Company&#146;s current compensation practices are aligned with the best interests of stockholders and anticipates taking into account any subsequent advisory vote
when making compensation decisions in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nominating and Corporate Governance Committee </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee is responsible for identifying, reviewing and evaluating candidates to serve as directors of
the Company (consistent with criteria approved by the Board of Directors), reviewing and evaluating incumbent directors, recommending to the Board of Directors candidates for election to the Board of Directors, making recommendations to the Board of
Directors regarding compensation for service on the Board of Directors and the committees thereof, making recommendations to the Board of Directors regarding the membership of the committees of the Board of Directors, assessing the performance of
the Board of Directors, developing a set of corporate governance principles for the Company and endeavoring to ensure that the Company&#146;s Board and Board Committees are operating in accord with best practices of corporate governance. The
Nominating and Corporate Governance Committee is currently composed of three<B></B>&nbsp;directors: Dr.&nbsp;Hove, Mr.&nbsp;Mitchell and Dr.&nbsp;Woosley (chair). All members of the Nominating and Corporate Governance Committee in 2017 were
independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards). The Nominating and Corporate Governance Committee met four<B></B>&nbsp;times during the 2017 fiscal year. The Nominating and Corporate Governance
Committee has adopted a written charter that is available to stockholders on the Company&#146;s website at www.arcabio.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Nominating and Corporate Governance Committee periodically reviews the compensation <FONT STYLE="white-space:nowrap">of&nbsp;non-employee&nbsp;Directors</FONT> for service on the Board of Directors and committees thereof. In 2015, the Nominating and
Corporate Governance Committee began a review of its Director compensation levels considering general market conditions in the life science industry, and in comparison to other clinical stage biopharmaceutical companies similarly situated to the
Company, and in early 2016, the Committee recommended, and the Board of Directors approved, revised compensation <FONT STYLE="white-space:nowrap">for&nbsp;non-employee&nbsp;Directors,</FONT> discussed in &#147;Director Compensation&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors has adopted a process for identifying and evaluating director nominees, including stockholder nominees. Before
recommending an individual to the Board of Directors for membership on the Board of Directors, the Nominating and Corporate Governance Committee canvasses its members and the Company&#146;s management team for potential candidates for the Board of
Directors. The Nominating and Corporate Governance Committee also uses its network of contacts to identify potential candidates and, if it deems appropriate, may also engage a professional search firm. The Nominating and Corporate Governance
Committee will consider stockholders&#146; recommendations for nominees to serve as director if notice is timely received by the Secretary of the Company. Candidates nominated by stockholders will be evaluated in the same manner as other candidates.
The Nominating and Corporate Governance Committee keeps the Board of Directors apprised of its discussions with potential nominees, and the names of potential nominees received from its current directors, management, and stockholders, if the
stockholder notice of nomination is timely made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Although the Board of Directors has not adopted a fixed set of minimum qualifications
for candidates for membership on the Board of Directors, the Nominating and Corporate Governance Committee generally considers several factors in its evaluation of a potential member, such as the candidate&#146;s education, professional background
and field of expertise including industry or academic experience in the pharmaceutical, biotechnology and cardiovascular fields, experience in corporate governance and management, the reasonable availability of the potential member to devote time to
the affairs of the Company, as well as any other criteria deemed relevant by the Board of Directors or the Nominating and Corporate Governance Committee. However, the Nominating and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the
Board of Directors, the operating requirements of the Company and the long-term interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other
factors as it deems appropriate given the current needs of the Board of Directors and the Company, to maintain a balance of knowledge, experience and capability. The Nominating and Corporate Governance Committee believes it is essential that Board
of Directors members come from a variety of backgrounds and experiences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the case of incumbent directors whose terms of office are set
to expire, the Nominating and Corporate Governance Committee reviews these directors&#146; overall contributions to the Company and the Board of Directors during their terms, including level of attendance, level of participation, quality of
performance and contribution to the Board of Directors&#146; responsibilities and actions, and any relationships and transactions that might impair the directors&#146; independence. In the case of new director candidates, the Nominating and
Corporate Governance Committee also determines whether the nominee is independent for Nasdaq and SEC purposes, which determination is based upon applicable Nasdaq<B></B>&nbsp;listing standards, applicable SEC rules and regulations and the advice of
counsel, if necessary. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board of
Directors. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates&#146; qualifications and then determines whether to recommend a nominee to the Board of Directors by majority vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:10pt; font-family:Times New Roman">Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for
election to the Board of Directors may do so by delivering a written recommendation to the Nominating and Corporate Governance Committee addressed to the Corporate Secretary, between 60 and 90 days before the
<FONT STYLE="white-space:nowrap">one-year</FONT> anniversary date of ARCA&#146;s last annual meeting of stockholders. Recommendations must include the full name of the proposed nominee, a description of the proposed nominee&#146;s business
experience for at least the previous five years, complete biographical information, a description of the proposed nominee&#146;s qualifications as a director, and a representation that the recommending stockholder is a beneficial or record owner of
ARCA&#146;s stock. Any such submission must be accompanied by the written consent of the proposed nominee to be named as a nominee and to serve as a director if elected. To date, the Nominating and Corporate Governance Committee has not rejected a
timely director nominee from a stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2017, the Nominating and Corporate Governance Committee did not pay any fees to assist in
the process of identifying or evaluating director candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>S<SMALL>TOCKHOLDER</SMALL> C<SMALL>OMMUNICATIONS</SMALL> W<SMALL>ITH</SMALL>
T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stockholders who wish to communicate with the
Board of Directors may do so by <FONT STYLE="white-space:nowrap">e-mail</FONT> by using the following email address: directors@arcabio.com; or by mail by following the directions as set forth on ARCA&#146;s website at www.arcabio.com, under the
section titled &#147;Corporate Governance&#148; and the subsection titled &#147;Governance Documents&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>ODE</SMALL> <SMALL>OF</SMALL>
B<SMALL>USINESS</SMALL> C<SMALL>ONDUCT</SMALL> <SMALL>AND</SMALL> E<SMALL>THICS</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has adopted the ARCA biopharma,
Inc. Code of Business Conduct and Ethics that applies to all officers, directors and employees. The Code of Business Conduct and Ethics is available on the Company&#146;s website at www.arcabio.com. If the Company makes any substantive amendments to
the Code of Business Conduct and Ethics or grants any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver on its website
and file any current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> required by applicable law or NASDAQ listing standards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>ROPOSAL</SMALL> 2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>R<SMALL>ATIFICATION</SMALL> <SMALL>OF</SMALL> S<SMALL>ELECTION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> I<SMALL>NDEPENDENT</SMALL>
R<SMALL>EGISTERED</SMALL> P<SMALL>UBLIC</SMALL> A<SMALL>CCOUNTING</SMALL> F<SMALL>IRM</SMALL> </B></P> <P STYLE="margin-top:30pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Audit Committee has selected KPMG
as the Company&#146;s independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2018, and has further directed that management submit the selection of the independent registered public accounting firm for
ratification by the stockholders at the Annual Meeting. KPMG has audited the Company&#146;s fiscal year financial statements since 2006. Representatives of KPMG are expected to be present at the Annual Meeting. They will have an opportunity to make
a statement if they so desire and will be available to respond to appropriate questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither the Company&#146;s Bylaws nor other
governing documents or law require stockholder ratification of the selection of KPMG as the Company&#146;s independent registered public accounting firm. However, the Board of Directors is submitting the selection of KPMG to the stockholders for
ratification as a matter of good corporate practice. If the stockholders fail to ratify the selection, the Audit Committee will reconsider whether to retain that firm. Even if the selection is ratified, the Audit Committee in its discretion may
direct the appointment of a different independent registered public accounting firm at any time during the year if they determine that such a change would be in the best interests of the Company and its stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The affirmative vote of the holders of a majority of the shares present in person or represented by proxy and entitled to vote at the Annual
Meeting will be required to ratify the selection of KPMG. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum, but are not counted for any purpose in determining whether this matter has been approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>RINCIPAL</SMALL> A<SMALL>CCOUNTANT</SMALL> F<SMALL>EES</SMALL> <SMALL>AND</SMALL> S<SMALL>ERVICES</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table represents aggregate fees billed, or expected to be billed, to the Company for the fiscal year ended December&nbsp;31,
2017, and December&nbsp;31, 2016, by KPMG, the Company&#146;s independent registered public accounting firm. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="55%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;Fiscal&nbsp;Year&nbsp;&nbsp;&nbsp;&nbsp;<BR>&nbsp;&nbsp;Ended&nbsp;2017&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Fiscal&nbsp;Year&nbsp;&nbsp;&nbsp;&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Ended&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$193,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$156,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$193,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$156,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="5" VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Audit Fees include fees for the (i)&nbsp;audit of the financial statements included in our Form <FONT STYLE="white-space:nowrap">10-K</FONT> for our fiscal years ended December&nbsp;31, 2017, and December&nbsp;31, 2016,
(ii)&nbsp;review of interim financial statements included on Forms <FONT STYLE="white-space:nowrap">10-Q</FONT> and (iii)&nbsp;attest, consent and review services normally provided by the accountant in connection with SEC filings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All fees described above were approved by the Audit Committee. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>P<SMALL>RE</SMALL><FONT STYLE="white-space:nowrap">-A</FONT><SMALL>PPROVAL</SMALL> P<SMALL>OLICIES</SMALL>
<SMALL>AND</SMALL> P<SMALL>ROCEDURES</SMALL> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The above services performed by the independent registered public accounting firm were <FONT
STYLE="white-space:nowrap">pre-approved</FONT> in accordance with the <FONT STYLE="white-space:nowrap">pre-approval</FONT> policy and procedures adopted by the Audit Committee. This policy describes the permitted audit, audit-related, tax, and other
services that the independent registered public accounting firm may perform. The policy also requires that the independent registered public accounting firm provide in writing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual description of all relationships between the independent registered public accounting firm and the client that may reasonably be thought to bear on independence; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">confirm that, in the independent registered public accounting firm&#146;s professional judgment, the independent registered public accounting firm is independent of the client under SEC requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discuss with the Audit Committee the independent registered public accounting firm&#146;s independence and the potential effects on its independence of performing any <FONT STYLE="white-space:nowrap">non-audit</FONT>
related services. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The services expected to be performed by our independent registered public accounting firm during the
subsequent fiscal year are presented to the Audit Committee for <FONT STYLE="white-space:nowrap">pre-approval.</FONT> Any <FONT STYLE="white-space:nowrap">pre-approval</FONT> must describe, in writing, the particular service or category of services.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Requests for audit, audit-related, tax, and other services not contemplated by those <FONT STYLE="white-space:nowrap">pre-approved</FONT>
services must be submitted to the Audit Committee for specific <FONT STYLE="white-space:nowrap">pre-approval.</FONT> Generally, <FONT STYLE="white-space:nowrap">pre-approval</FONT> is considered at the Audit Committee&#146;s regularly scheduled
meetings. However, the authority to grant specific <FONT STYLE="white-space:nowrap">pre-approval</FONT> between meetings, as necessary, has been delegated to the chairman of the Audit Committee. If the chairman is not available, the other two Audit
Committee members together have the authority to grant specific <FONT STYLE="white-space:nowrap">pre-approval</FONT> between meetings. The chairman or the other members must update the Audit Committee at the next regularly scheduled meeting of any
services that were granted specific <FONT STYLE="white-space:nowrap">pre-approval.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Audit Committee <FONT
STYLE="white-space:nowrap">pre-approved</FONT> all audit related, tax and other services rendered in 2017 and did not rely on the waiver of <FONT STYLE="white-space:nowrap">pre-approval</FONT> requirement provided by paragraph (c)(7)(i)(C) of <FONT
STYLE="white-space:nowrap">Rule&nbsp;2-01</FONT> of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-X</FONT> promulgated under the Exchange Act. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 2. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>ECURITY</SMALL> O<SMALL>WNERSHIP</SMALL> <SMALL>OF</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ERTAIN</SMALL> B<SMALL>ENEFICIAL</SMALL> O<SMALL>WNERS</SMALL> <SMALL>AND</SMALL> M<SMALL>ANAGEMENT</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Principal Stockholders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following
table sets forth certain information regarding the ownership of the Company&#146;s Common Stock as of April&nbsp;4, 2018, by: (i)&nbsp;each director and nominee for director, (ii)&nbsp;each of our named executive officers, (iii)&nbsp;all executive
officers and directors of the Company as a group, and (iv)&nbsp;all those known by the Company to be beneficial owners of more than five percent of its Common Stock. Unless otherwise noted below, the address of each beneficial owner listed on the
table is c/o ARCA biopharma, Inc., 11080 CirclePoint Road, Suite&nbsp;140, Westminster, Colorado, 80020. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have determined beneficial
ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the table below have sole voting and investment power with
respect to all shares of Common Stock that they beneficially own, subject to applicable community property laws. The table is based upon information supplied by officers, directors and principal stockholders and Schedules 13G or 13D, Form 4s or
other ownership reports filed with the SEC. For purposes of this table, certain of our outstanding warrants that may be exercisable for fractional shares have been rounded down to the nearest whole number. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In computing the number of shares of Common Stock beneficially owned by a person and the percentage ownership of that person, we deemed
outstanding shares of Common Stock subject to options, restricted stock units, or warrants held by that person that are currently exercisable or exercisable within 60 days of April&nbsp;4, 2018. We did not deem these shares outstanding, however, for
the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The percentages below are based on 13,923,825 shares of our Common
Stock outstanding as of April&nbsp;4,&nbsp;2018. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="80%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><B><U>Beneficial
Owner&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Percentage&nbsp;of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Directors and Named Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow, M.D., Ph.D. (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">198,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer (2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,785</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher D. Ozeroff (3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,042</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Linda Grais, M.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,472</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert E. Conway (5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,275</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Raymond L. Woosley (6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,397</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dan J. Mitchell (7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,772</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anders Hove, M.D. (8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,334</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All current directors and executive officers as a<BR>group (9 persons) (9)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">474,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.33</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tekla Life Sciences Investors (10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">811,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.83</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1% of our Common Stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes the following owned by (i)&nbsp;Investocor Trust: 19,986 shares, Dr.&nbsp;Bristow is the sole trustee of Investocor Trust; (ii)&nbsp;NFS as Custodian for Michael Bristow&#146;s IRA: (a) 25,459 shares and (b)
17,821 shares issuable upon the exercise of warrants, which warrants are immediately exercisable; (iii) 5,578 shares issuable upon the exercise of warrants, which warrants are immediately exercisable and held directly; and (iv)&nbsp;options to
purchase 88,027 shares that are exercisable within 60 days of April&nbsp;4, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 31,632 shares that are exercisable within 60 days of April&nbsp;4, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 29,525 shares that are exercisable within 60 days of April&nbsp;4, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 25,472 shares that are exercisable within 60 days of April&nbsp;4, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 24,275 shares that are exercisable within 60 days of April&nbsp;4, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 24,397 shares that are exercisable within 60 days of April&nbsp;4, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 23,772 shares that are exercisable within 60 days of April&nbsp;4, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Includes options to purchase 13,334 shares that are exercisable within 60 days of April&nbsp;4, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">See Notes (1)&nbsp;through (8) above. Also, includes additional options to purchase 27,137 shares that are exercisable within 60 days of April&nbsp;4, 2018 beneficially owned by our executive officers not listed by name
in the table above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Based solely on a Schedule 13G filed with the SEC on February&nbsp;12, 2018. Tekla Capital Management LLC (&#147;TCM&#148;), as an investment adviser to Tekla Life Sciences Investors (&#147;HQL&#148;), shares beneficial
ownership over the shares held by HQL. Each of TCM and Daniel R. Omstead, through his control of TCM, has sole power to dispose of the shares beneficially owned by HQL. Neither TCM nor Daniel R. Omstead has the sole power to vote or direct the vote
of the shares beneficially owned by HQL, which power resides in the fund&#146;s Board of Trustees. TCM carries the voting of shares under written guidelines established by the funders Board of Trustees. The address for Tekla Life Sciences Investors
is 100 Federal Street, 19th Floor, Boston, MA 02110. </TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>ECTION</SMALL>&nbsp;16(<SMALL>A</SMALL>)
B<SMALL>ENEFICIAL</SMALL> O<SMALL>WNERSHIP</SMALL> R<SMALL>EPORTING</SMALL> C<SMALL>OMPLIANCE</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Section&nbsp;16 of the Exchange
Act requires the Company&#146;s directors and executive officers, and persons who own more than 10% of its Common Stock, to file with the SEC initial reports of ownership and reports of changes in ownership of Common Stock of the Company. Such
persons are required by SEC regulation to furnish us with copies of all Section&nbsp;16(a) forms that they file. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To the Company&#146;s
knowledge, based solely upon its review of the copies of such reports furnished to it and written representations that no other reports were required, during the fiscal year ended December&nbsp;31, 2017, all Section&nbsp;16(a) filing requirements
applicable to its officers, directors and ten percent beneficial owners were complied with. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XECUTIVE</SMALL> O<SMALL>FFICERS</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding each of the executive officers as of March&nbsp;31, 2018. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><B><U>Name&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael R. Bristow, M.D., Ph.D.*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">73</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Brian L. Selby</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">56</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President, Finance and Chief Accounting Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Thomas A. Keuer</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Christopher D. Ozeroff</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Secretary, Senior Vice President and General Counsel</TD></TR>
</TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Also serves as a director. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Michael R. Bristow, M.D., Ph.D.</I> See Mr.&nbsp;Bristow&#146;s
biography in Proposal Number 1 &#150; Election of Directors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Brian L. Selby</I>.&nbsp;Mr.&nbsp;Selby has served as the Company&#146;s
Vice President, Finance and Chief Accounting Officer since December 2014.&nbsp;Previously, Mr.&nbsp;Selby served as the Company&#146;s Controller from 2007 to 2014.&nbsp;Prior to joining the Company, Mr.&nbsp;Selby served as the Controller for
Myogen, Inc., a publicly traded pharmaceutical company subsequently acquired by Gilead, from 2004 to 2007.&nbsp;Prior to Myogen, Mr.&nbsp;Selby served as the Controller for several private and publicly traded companies and earlier in his career was
an audit professional with Deloitte. Mr.&nbsp;Selby received his M.S. in Accounting from the University of Colorado and received his B.S., in Business Administration and Finance from Colorado State University, and is a certified public accountant.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Thomas A. Keuer</I>. Mr.&nbsp;Keuer has served as the Company&#146;s Chief Operating Officer since December 2014. Mr.&nbsp;Keuer served
as the Company&#146;s Executive Vice President, Pharmaceutical Operations from 2006 to 2014. Prior to joining the Company, Mr.&nbsp;Keuer served as the SVP of Operations for Insmed, Inc. from 2004 to 2006. Prior to Insmed, Mr.&nbsp;Keuer served as
the VP of Engineering for Baxter Healthcare from 1998 to 2004. Prior to Baxter, Mr.&nbsp;Keuer served as the VP of Operations for Somatogen, Inc. Mr.&nbsp;Keuer received his M.S. in Biochemical Engineering from Rice University and received his B.S.
in Chemical Engineering from the University of Texas, Austin. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Christopher D. Ozeroff</I>. Mr.&nbsp;Ozeroff is a <FONT
STYLE="white-space:nowrap">co-founder</FONT> of ARCA. Mr.&nbsp;Ozeroff has served as the Company&#146;s Senior Vice President, General Counsel and Secretary since 2009, has served as the Company&#146;s General Counsel and Secretary since the
Company&#146;s founding, and has also served as Executive Vice President, Business Development from 2004 to 2009. Prior to joining the Company, Mr.&nbsp;Ozeroff was a partner with the law firm of Hogan&nbsp;&amp; Hartson L.L.P., where he practiced
in such areas as finance, acquisitions, public offerings, and licensing. Mr.&nbsp;Ozeroff completed his undergraduate degree at Stanford University and his law degree at the University of Chicago Law School. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows for the fiscal years ended December&nbsp;31, 2017 and/or December&nbsp;31, 2016, compensation awarded to, paid to, or
earned by the Company&#146;s principal executive officer and its two most highly compensated executive officers as of December&nbsp;31, 2017, collectively, the Named Executive Officers: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>S<SMALL>UMMARY</SMALL> C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> <SMALL>FOR</SMALL> F<SMALL>ISCAL</SMALL> 2017 <SMALL>AND</SMALL>
2016 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B></B>&nbsp;&nbsp;Name and Principal Position<B></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B></B>Year<B></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B></B>Salary<BR>($)(1)<B></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Option<BR>Awards<BR>($)(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Stock<BR>Awards</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">($)(2)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive<BR>Plan&nbsp;Awards<BR>($)(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">All Other<BR>Compensation<BR>($)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000">Total ($)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Michael R. Bristow</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">302,856</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">137,281</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">91,300</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">16,256</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">547,693</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">169,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">16,227</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">572,256</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Thomas A. Keuer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">301,642</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">80,428</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">20,597</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">457,167</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right"> 2016<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right"> 292,852<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right"> 97,174<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right"> 55,200<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> 17,782<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom" ALIGN="right"> 463,008<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD NOWRAP VALIGN="bottom"> &nbsp;<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Christopher D. Ozeroff</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;Secretary, Senior Vice President and General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">296,011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">76,654</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">12,110</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">438,275</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5,381</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">439,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported under &#147;Salary&#148; in the above table represent the actual amounts paid during the calendar year. Because the Company&#146;s actual pay dates do not always coincide with the first and last
days of the year, these amounts may differ from the base salary amounts authorized by the Company&#146;s Board of Directors and described in the narrative that follows. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported under &#147;Option Awards&#148; and &#147;Stock Awards&#148; in the above table reflect the grant date fair value of these awards as determined in accordance with Financial Accounting Standards
Board Accounting Standards Codification Topic 718, Compensation &#150; Stock Compensation, excluding the effects of estimated forfeitures. The value of stock option awards was estimated using the Black-Scholes option-pricing model. The valuation
assumptions used in the valuation of option grants may be found in Note 8 to the Company&#146;s financial statements included in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and
filed with the SEC on March&nbsp;22, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Represents cash bonuses earned under the 2017 and 2016 Bonus Plans. Cash bonuses earned and reported above in 2016 were paid in 2017, and cash bonuses earned and reported above in 2017 were paid in 2018. See
&#147;Executive Compensation&#148; for descriptions of the 2017 and 2016 Bonus Plans. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Narrative Disclosure to Summary Compensation Table </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employment Agreements or Arrangements </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Michael R. Bristow, M.D., Ph.D.</I> Dr.&nbsp;Bristow serves as the Company&#146;s President and Chief Executive Officer under an Employment
and Retention Agreement that was amended and restated as of June&nbsp;4, 2008, and further amended pursuant to a Waiver and Amendment Agreement executed as of June&nbsp;13, 2013. Pursuant to such employment agreement, Dr.&nbsp;Bristow is permitted
to continue his academic work for the University of Colorado Health Sciences Center and for the Cardiovascular Institute, so long as it does not interfere with his duties as President and Chief Executive Officer of ARCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2017, the Board of Directors approved a cash bonus of $92,300 for Dr.&nbsp;Bristow. The cash bonus was earned under the
2016 Bonus Plan for services rendered in 2016. See &#147;<I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation</I>&#148; below for descriptions of the 2016 Bonus Plan. The Board of Directors also approved a 2017 base
salary of $304,219 for Dr.&nbsp;Bristow. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2018, the Board of Directors approved a cash bonus of $91,300 for
Dr.&nbsp;Bristow. The cash bonus was earned under the 2017 Bonus Plan for services rendered in 2017. See &#147;<I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation</I>&#148; below for descriptions of the 2017 Bonus Plan.
There were no changes to Dr.&nbsp;Bristow&#146;s salary for 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the Company terminates Dr.&nbsp;Bristow&#146;s employment without
&#147;cause,&#148; or if Dr.&nbsp;Bristow terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Dr.&nbsp;Bristow a severance payment equivalent to (i) (a) 12
months of his base salary, if such termination occurs on the same day as or within 13 months after a change of control of the Company, or (b)&nbsp;six months of his base salary if such termination does not occur on the same day as or within 13
months after a change of control of the Company, (ii)&nbsp;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the fiscal year in which his employment
terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs to continue group health insurance benefits under COBRA for 6 months, whether he elects or is eligible to receive COBRA (provided, that even if he
does not elect or is not eligible to receive COBRA, he will receive the equivalent of such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses paid by him not to exceed the costs that the benefits
would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 6 months of base salary, which additional payment would extend the covenants and obligations under
Dr.&nbsp;Bristow&#146;s Employee Intellectual Property, Confidentiality and <FONT STYLE="white-space:nowrap">Non-Compete</FONT> Agreement for such additional period. The severance payment is conditioned on the execution by Dr.&nbsp;Bristow of a
legal release in a form acceptable to the Company. A termination for &#147;cause&#148; includes Dr.&nbsp;Bristow&#146;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be
materially harmful to the Company; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of
his employment agreement or his Employee Intellectual Property, Confidentiality and <FONT STYLE="white-space:nowrap">Non-Compete</FONT> Agreement, or any other agreement, with the Company. &#147;Good reason&#148; includes a relocation by us of
Dr.&nbsp;Bristow&#146;s normal work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and the Company&#146;s unilateral decision to significantly and detrimentally reduce
Dr.&nbsp;Bristow&#146;s job responsibilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Thomas A. Keuer.</I> Mr.&nbsp;Keuer serves as the Company&#146;s Chief Operating Officer
under an Amended and Restated Employment Agreement that was effective as of January&nbsp;1, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under his employment agreement,
Mr.&nbsp;Keuer is entitled to receive an annual base salary of $280,000, subject to annual increases if approved by the Company&#146;s Board of Directors or Compensation Committee and is eligible to receive an annual bonus as determined by the Board
of Directors or Compensation Committee in its sole discretion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2017, the Board of Directors approved a cash bonus of $55,200 for
Mr.&nbsp;Keuer. The cash bonus was earned under the 2016 Bonus Plan for services rendered in 2016. See &#147;<I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation</I>&#148; below for descriptions of the 2016 Bonus Plan.
The Board of Directors also approved a 2017 base salary of $303,000 for Mr.&nbsp;Keuer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2018, the Board of Directors
approved a cash bonus of $54,500 for Mr.&nbsp;Keuer. The cash bonus was earned under the 2017 Bonus Plan for services rendered in 2017. See &#147;<I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation</I>&#148; below for
descriptions of the 2017 Bonus Plan. There were no changes to Mr.&nbsp;Keuer&#146;s salary for 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the Company terminates
Mr.&nbsp;Keuer&#146;s employment without &#147;cause,&#148; or if Mr.&nbsp;Keuer terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Mr.&nbsp;Keuer a
severance payment equivalent to (i)&nbsp;(a) 12 months of his base salary, if such termination occurs on the same day as or within 13 months after a change of control of the Company, or (b)&nbsp;six months of his base salary if such termination does
not occur on the same day as or within 13 months after a change of control of the Company, (ii)&nbsp;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the
fiscal year in which his employment terminated to be paid at the same time that such incentive bonus would have been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs to continue group health insurance benefits under COBRA for (x) 12 months, if such termination occurs on the same day as or within 13 months after a change of control of the Company, or
(y)&nbsp;six months if such termination does not occur on the same day as or within 13 months after a change of control of the Company, whether he elects or is eligible to receive COBRA (provided, in either event, that even if he does not elect or
is not eligible to receive COBRA, he will receive the equivalent of such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses paid by him not to exceed the costs that the benefits would equal under
COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance equal to up to 12 months of base salary, which additional payment would extend the covenants and obligations under Mr.&nbsp;Keuer&#146;s
Employee Intellectual Property, Confidentiality and <FONT STYLE="white-space:nowrap">Non-Compete</FONT> Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&nbsp;Keuer of a legal release in a form
acceptable to the Company. A termination for &#147;cause&#148; includes Mr.&nbsp;Keuer&#146;s willful misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to the
Company; refusal, unwillingness, failure, or inability to perform his material job duties or habitual absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement
or his Employee Intellectual Property, Confidentiality and <FONT STYLE="white-space:nowrap">Non-Compete</FONT> Agreement, or any other agreement, with the Company. &#147;Good reason&#148; includes a relocation by us of Mr.&nbsp;Keuer&#146;s normal
work location greater than 30 miles; a decrease in current base salary by more than 15%, with certain exceptions; and the Company&#146;s unilateral decision to significantly and detrimentally reduce Mr.&nbsp;Keuer&#146;s job responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>Christopher D. Ozeroff.</I> Mr.&nbsp;Ozeroff serves as the Company&#146;s Senior Vice President and General Counsel under an Employment and
Retention Agreement that was amended and restated as of June&nbsp;12, 2008, and further amended pursuant to a Waiver and Amendment Agreement executed as of June&nbsp;13, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under his employment agreement, Mr.&nbsp;Ozeroff is entitled to receive an annual base salary of $259,000, subject to annual increases if
approved by the Company&#146;s Board of Directors or Compensation Committee and is eligible to receive an annual bonus as determined by the Board of Directors or Compensation Committee in its sole discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On February&nbsp;16, 2017, the Board of Directors approved a cash bonus of $54,100 for Mr. Ozeroff. The cash bonus was earned under the 2016
Bonus Plan for services rendered in 2016. See &#147;<I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation</I>&#148; below for descriptions of the 2016 Bonus Plan. The Board of Directors also approved a 2017 base salary of
$297,343 for Mr. Ozeroff. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;1, 2018, the Board of Directors approved a cash bonus of $53,500 for Mr.&nbsp;Ozeroff. The cash
bonus was earned under the 2017 Bonus Plan for services rendered in 2017. See &#147;<I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation</I>&#148; below for descriptions of the 2017 Bonus Plan. There were no changes
Mr.&nbsp;Ozeroff&#146;s salary for 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the Company terminates Mr.&nbsp;Ozeroff&#146;s employment without &#147;cause,&#148; or if
Mr.&nbsp;Ozeroff terminates his employment with &#147;good reason&#148; (as these terms are defined in his employment agreement), the Company has agreed to pay Mr.&nbsp;Ozeroff a severance payment equivalent to (i) (a) 12 months of his base salary,
if such termination occurs on the same day as or within 13 months after a change of control of the Company, or (b)&nbsp;six months of his base salary if such termination does not occur on the same day as or within 13 months after a change of control
of the Company, (ii)&nbsp;a pro rata portion of any bonus compensation under any employee bonus plan that has been approved by the Board of Directors payable to him for the fiscal year in which his employment terminated to be paid at the same time
that such incentive bonus would have been paid had the termination not occurred, and (iii)&nbsp;reimbursement to cover <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs to continue group health
insurance benefits under COBRA for 6 months, whether he elects or is eligible to receive COBRA (provided, that even if he does not elect or is not eligible to receive COBRA, he will receive the equivalent of such <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses paid by him not to exceed the costs that the benefits would equal under COBRA if he were so eligible). In addition, ARCA may elect in its sole discretion, to pay additional severance
equal to up to 6 months of base salary, which additional payment would extend the covenants and obligations under Mr.&nbsp;Ozeroff&#146;s Employee Intellectual Property, Confidentiality and <FONT STYLE="white-space:nowrap">Non-Compete</FONT>
Agreement for such additional period. The severance payment is conditioned on the execution by Mr.&nbsp;Ozeroff of a legal release in a form acceptable to the Company. A termination for &#147;cause&#148; includes Mr.&nbsp;Ozeroff&#146;s willful
misconduct, gross negligence, theft, fraud, or other illegal or dishonest conduct, any of which are considered to be materially harmful to the Company; refusal, unwillingness, failure, or inability to perform his material job duties or habitual
absenteeism; or violation of fiduciary duty, violation of any duty of loyalty, or material breach of any material term of his employment agreement or his Employee Intellectual Property, Confidentiality and
<FONT STYLE="white-space:nowrap">Non-Compete</FONT> Agreement, or any other agreement, with the Company. &#147;Good reason&#148; includes a relocation by us of Mr.&nbsp;Ozeroff&#146;s normal work location greater than 30 miles; a decrease in current
base salary by more than 15%, with certain exceptions; and the Company&#146;s unilateral decision to significantly and detrimentally reduce Mr.&nbsp;Ozeroff&#146;s job responsibilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2007, the Compensation Committee and the Board of Directors of ARCA established a bonus structure for its entire executive team.
The philosophy employed was to create incentives for the executive officers to achieve key corporate goals. The Compensation Committee retained discretion to change the bonus structure and the bonus payment amounts as it considered appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2016 Cash Bonus Plan </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
February&nbsp;16, 2017, the Board of Directors approved cash bonuses for certain employees. The cash bonuses were paid in 2017 for performance in 2016, including for attainment of the Company&#146;s 2016 Goals under its 2016 Cash Bonus Plan (the
&#147;2016 Goals&#148;), as determined by the Compensation Committee. The 2016 bonuses were based on the Board of Directors&#146; determination with respect to the Company&#146;s achievement of the 2016 Goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The 2016 Goals were based on (1)&nbsp;enrollment of <FONT STYLE="white-space:nowrap">GENETIC-AF</FONT> (2)&nbsp;development pipeline
objectives, and (3)&nbsp;corporate transaction objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2017 Cash Bonus Plan </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors has set corporate goals for 2017 (the &#147;2017 Goals&#148;), which may be updated at the Board of Directors&#146;
discretion during 2017. Attainment of the 2017 Goals is a prerequisite to the payment of any awards to employees under the Company&#146;s 2017 Cash Bonus Plan, including executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The amount payable to each employee is set as a target percentage of each employee&#146;s annual salary, or the target bonus percentage
(&#147;TBP&#148;), but employees, including executive officers, may receive more or less than 100% of their TBP, based upon corporate goal achievement, individual performance and the discretion of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To receive a cash bonus (if any), each individual employee must be actively employed by the Company, and in good standing, on
December&nbsp;31, 2017. Employees hired after January&nbsp;1, 2017, will have their cash bonus (if any) prorated based on the percentage of time the employee worked at ARCA in 2017. The 2017 Goals are based on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(1) the <FONT STYLE="white-space:nowrap">GENETIC-AF</FONT> Data and Safety Monitoring Board analysis and enrollment of <FONT STYLE="white-space:nowrap">GENETIC-AF;</FONT> (2)&nbsp;financing
goals; and (3)&nbsp;corporate transaction objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2018 Cash Bonus Plan </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Compensation Committee and Board of Directors have not approved a bonus structure or goals for 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Elements of Executive Compensation Program </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The remaining elements of the Company&#146;s executive compensation program, like its broader employee compensation programs, are intended to
make the Company&#146;s overall compensation program competitive with those of its peer companies, keeping in mind the constraints imposed by the Company&#146;s reliance on capital markets as a primary source of cash. The remaining elements of the
Company&#146;s executive compensation program, (401(k) Plan, Medical, Dental, and Vision Plans, Life and Disability Insurance) are available to all Company employees. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>QUITY</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>LAN</SMALL> I<SMALL>NFORMATION</SMALL> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth information as of December&nbsp;31, 2017, for all of our equity compensation plans: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No.&nbsp;of&nbsp;Securities</B><br><B>to&nbsp;be&nbsp;Issued&nbsp;Upon</B><br><B>Exercise&nbsp;of<BR>Outstanding<BR>Options or</B><br><B>Upon</B><br><B>Vesting
of<BR>Restricted</B><br><B>Stock</B><br><B>Units</B><br><B>(a)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average<BR>Exercise</B><br><B>Price of<BR>Outstanding</B><br><B>Options</B><br><B>($)</B><br><B>(b)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No.&nbsp;of&nbsp;Securities</B><br><B>Remaining</B><br><B>Available for</B><br><B>Future&nbsp;Issuance&nbsp;Under<BR>Equity Compensation</B><br><B>Plans
Excluding<BR>Securities</B><br><B>Reflected in<BR>Column(a)</B><br><B>(c)</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">627,143</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">610,194</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">627,143</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">6.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">610,194</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;17, 2013, our stockholders approved the ARCA biopharma, Inc. 2013 Equity Incentive Plan (the &#147;2013 Plan&#148;) at the
Company&#146;s 2013 annual meeting of stockholders.&nbsp;The 2013 Plan is the successor to the Amended and Restated ARCA biopharma, Inc. 2004 Equity Incentive Plan (the &#147;2004 Plan&#148;). On June&nbsp;9, 2016, our stockholders approved the
Amended 2013 Plan. A description of the 2013 Plan and the Amended 2013 Plan is set forth in Note 8 to the Company&#146;s financial statements included in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2017, and filed with the SEC on March&nbsp;22, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Compensation Risks </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">ARCA believes its approach to goal setting, setting of targets with payouts at multiple levels of performance, and evaluation of performance
results assist in mitigating excessive risk-taking that could harm the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
value or reward poor judgment by its executives. ARCA believes several features of the Company&#146;s programs reflect sound risk management practices. ARCA believes it has allocated compensation
among base salary and short and long-term compensation target opportunities in such a way as to not encourage excessive risk-taking. The multi-year vesting of equity awards properly accounts for the time horizon of risk. Furthermore, the
Compensation Committee assesses and monitors whether any of ARCA&#146;s compensation policies and programs has the potential to encourage excessive risk-taking on an annual basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>UTSTANDING</SMALL> E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL> <SMALL>AT</SMALL>
F<SMALL>ISCAL</SMALL> <SMALL>YEAR</SMALL> <SMALL>END</SMALL> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows for the fiscal year ended December&nbsp;31,
2017, certain information regarding outstanding equity awards at fiscal year end for the Named Executive Officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A description of the
equity incentive plans we maintain is set forth in Note 8 to the Company&#146;s financial statements included in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and filed with the SEC
on March&nbsp;22, 2018. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:137pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:137pt"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:198pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:198pt"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:56pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:56pt"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:57pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:57pt"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="19" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:22.50pt; display:inline; font-size:9pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options</B><br><B>(#)&nbsp;Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="5"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233.94</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/23/2019</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">380</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124.74</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2020</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94.08</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2021</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,142</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/16/2023</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,260</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/16/2023</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,050</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.65</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2024</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,494</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/11/2025</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,600</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,600&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(3)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/8/2026</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,667</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,333&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(4)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2027</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="9"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer, Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78.12</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/12/2018</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216.30</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/14/2018</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">121.80</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/25/2019</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124.74</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2020</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94.08</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2021</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,775</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/16/2023</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,428</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.85</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/14/2023</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.65</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2024</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,841</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/11/2025</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,800</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,800&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(3)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/8/2026</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,200&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(4)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2027</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Ozeroff, Secretary, Senior Vice President and General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124.74</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/18/2020</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94.08</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5/20/2021</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,091</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.66</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/16/2023</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(1)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.65</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/26/2024</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,747</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(2)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.69</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/11/2025</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,400</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,400&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(3)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/8/2026</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,667</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,333&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">(4)(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.50</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" >&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/15/2027</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Options vest in monthly installments through February&nbsp;27, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Options vest in 36 monthly installments measured from February&nbsp;12, 2015. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Options vest in 36 monthly installments measured from June&nbsp;9, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Options vest in 36 monthly installments measured from February&nbsp;16, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">In the event of a change in control of the Company, 50% of the unvested shares subject to this award shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on
the earlier of (i)&nbsp;the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the closing date or (ii)&nbsp;involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:22.50pt; display:inline; font-size:9pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Number&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Shares&nbsp;or&nbsp;Units&nbsp;of&nbsp;Stock<BR>That Have Not Vested<BR><U>(#) Unvested</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Market&nbsp;Value&nbsp;of<BR>Shares&nbsp;or&nbsp;Units&nbsp;of<BR>Stock That Have<BR>Not
Vested</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><U>($)</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow, President and Chief Executive Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,025&nbsp;(1)(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2,291&nbsp;(2)(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer, Chief Operating Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1,222&nbsp;(1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,207&nbsp;(2)(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Christopher Ozeroff, Secretary, Senior Vice President and General Counsel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,222&nbsp;(1)(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1,145&nbsp;(2)(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Restricted Stock Units vest on February&nbsp;27, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Restricted Stock Units vest on April&nbsp;2, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">In the event of a change in control of the Company, 50% of the unvested shares subject to this award shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on
the earlier of (i)&nbsp;the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the closing date or (ii)&nbsp;involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.
</TD></TR></TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option Exercises And Stock Vested </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding option exercises and restricted stock units that vested during the year ended
December&nbsp;31, 2017, with respect to the Named Executive Officers: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom"><B>Name</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Acquired&nbsp;on<BR>Exercise<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized<BR>on&nbsp;Exercise<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares<BR>Acquired&nbsp;on<BR>Vesting<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value<BR>Realized<BR>on&nbsp;Vesting<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael R. Bristow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas A. Keuer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,428</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,071</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Ozeroff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The value realized on exercise of the options equals the difference between the market price of the underlying stock at exercise and the exercise or base price of the options, multiplied by the number of shares acquired
on exercise. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The value realized on vesting of restricted stock units equals the market value of the Company&#146;s Common Stock on the vesting date, multiplied by the number of shares that vested. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table shows for the fiscal year ended December&nbsp;31, 2017, certain information with respect to the compensation of all <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors of the Company: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL>
<SMALL>FOR</SMALL> F<SMALL>ISCAL</SMALL> 2017 (1) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="85%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Fees<BR>Earned<BR>or&nbsp;Paid&nbsp;in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt"><B>Option<BR>Awards<BR>($)(2)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Nonqualified<BR>Deferred<BR>Compensation<BR>Earnings<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>All Other<BR>Compensation<BR>($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><FONT STYLE="font-size:8pt"><B>Total&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Linda Grais, M.D. (3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Raymond L. Woosley, M.D. (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Robert E. Conway (5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">92,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Dan J. Mitchell (6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Anders Hove (7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Bristow, our President and Chief Executive Officer, was also a director during the year ended December&nbsp;31, 2017, but did not receive any additional compensation for his service as a director.
Dr.&nbsp;Bristow&#146;s compensation as an executive officer is set forth above under &#147;Executive Compensation&#151;Summary Compensation Table.&#148; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported under &#147;Option Awards&#148; in the above table reflect the aggregate grant date fair value of these awards as determined in accordance with Financial Accounting Standards Board Accounting
Standards Codification Topic 718, Compensation &#150; Stock Compensation, excluding the effects of estimated forfeitures. The value of stock option awards was estimated using the Black-Scholes option-pricing model. The valuation assumptions used in
the valuation of option awards may be found in Note 8 to the Company&#146;s financial statements included in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and filed with the SEC on
March&nbsp;22, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2017, for Dr.&nbsp;Grais was 22,138, of which all shares were fully vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2017, for Dr.&nbsp;Woosley was 21,063, of which all shares were fully vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2017, for Mr.&nbsp;Conway was 20,941, of which all shares were fully vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2017, for Mr.&nbsp;Mitchell was 20,438, of which all shares were fully vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">The aggregate number of shares issuable upon exercise of option awards outstanding at December&nbsp;31, 2017, for Dr.&nbsp;Hove was 10,000, of which 8,334 shares were fully vested. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In 2016, the Company revised its compensation plan for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors to provide that <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors will be compensated for their service on the Board of Directors, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual retainer fee of $35,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As additional compensation for their services, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive (i), upon joining the Board of Directors, an initial option grant to purchase 10,000 shares
of the Company&#146;s Common Stock under the Amended 2013 Plan and (ii), on an annual basis, an annual option grant to purchase 8,000 shares of the Company&#146;s Common Stock under the Amended 2013 Plan; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Chairman of the Board of Directors will receive an additional annual retainer fee of $25,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The Audit Committee chair will receive an additional annual retainer fee of $15,000; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The chairs of the Compensation Committee and the Nominating and Corporate Governance Committee will each receive an additional annual retainer fee of $10,000; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each <FONT STYLE="white-space:nowrap">non-chair</FONT> member of the Audit Committee will receive an additional annual retainer fee of $7,500; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9679;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each <FONT STYLE="white-space:nowrap">non-chair</FONT> member of the Compensation Committee and the Nominating and Corporate Governance Committees will receive an additional annual retainer fee of $5,000.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the February&nbsp;16, 2017, meeting of the Board of Directors, the Board of Directors awarded
annual stock option grants to the Company&#146;s <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Mr.&nbsp;Mitchell, Dr.&nbsp;Grais, Dr.&nbsp;Woosley and Mr.&nbsp;Conway each were granted options to purchase 8,000 shares of Common
Stock under the Amended 2013 Plan vesting over one year. In addition, the Board granted an option to purchase 10,000 shares of Common Stock to Dr.&nbsp;Hove in connection with his joining the Board. These options were issued under the Amended 2013
Plan and vest over one year. The purchase price for the options issued on February&nbsp;16, 2017, was $2.50 per share, which was equal to the closing price of the Company&#146;s Common Stock on Nasdaq on the date of the grant. If the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s service terminates in connection with or at any time following a change in control, then any unexpired options that remain unvested shall become fully vested. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the March&nbsp;1, 2018, meeting of the Board of Directors, the Board of Directors awarded annual stock option grants to the Company&#146;s <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. Mr.&nbsp;Mitchell, Dr.&nbsp;Grais, Dr.&nbsp;Woosley, Mr.&nbsp;Conway and Dr.&nbsp;Hove each were granted options to purchase 8,000 shares of Common Stock under the Amended 2013 Plan vesting
over one year. The purchase price for the options issued on March&nbsp;1, 2018, was $0.72 per share, which was equal to the closing price of the Company&#146;s Common Stock on Nasdaq on the date of the grant. If the
<FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s service terminates in connection with or at any time following a change in control, then any unexpired options that remain unvested shall become fully vested. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ERTAIN</SMALL> R<SMALL>ELATIONSHIPS</SMALL> <SMALL>AND</SMALL> R<SMALL>ELATED</SMALL> T<SMALL>RANSACTIONS</SMALL> </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Certain Transactions With or Involving Related Persons </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a summary of transactions since January&nbsp;1, 2016, to which we have been a party in which the amount involved exceeded the
lesser of $120,000 or one percent of the average of our total assets at fiscal years ended 2017, and in which any of our executive officers, directors or holders of more than 5% of our capital stock, or any member of the immediate family of any of
the foregoing persons, had or will have a direct or indirect material interest, other than compensation arrangements disclosed above under the heading &#147;Executive Compensation&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transactions With the Company&#146;s President and Chief Executive Officer </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has entered into unrestricted research grants with the academic research laboratory of Dr.&nbsp;Bristow, the Company&#146;s
President and Chief Executive Officer, at the University of Colorado. Funding of any unrestricted research grants is contingent upon the Company&#146;s financial condition, and can be deferred or terminated at the Company&#146;s discretion. Total
expense under these arrangements for the years ended December&nbsp;31, 2017 and 2016 was approximately $418,000 and $427,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policies
and Procedures for Related Party Transactions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our Audit Committee reviews and approves all related party transactions. This review
covers any material transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, and a related party had or will have a direct or indirect material
interest, including, purchases of goods or services by or from the related party or entities in which the related party has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>H<SMALL>OUSEHOLDING</SMALL> <SMALL>OF</SMALL> P<SMALL>ROXY</SMALL> M<SMALL>ATERIALS</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The SEC has adopted rules that permit companies and intermediaries (e.g., brokers) to satisfy the delivery requirements for Notices
of Internet Availability of Proxy Materials or other Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single Notice of Internet Availability of Proxy Materials or other Annual Meeting
materials addressed to those stockholders. This process, which is commonly referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This year, a number of brokers with account holders who are ARCA biopharma, Inc. stockholders will be &#147;householding&#148; the
Company&#146;s proxy materials. A single Notice of Internet Availability of Proxy Materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have
received notice from your broker that they will be &#147;householding&#148; communications to your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish
to participate in &#147;householding&#148; and would prefer to receive a separate Notice of Internet Availability of Proxy Materials, please notify your broker or ARCA biopharma, Inc. Direct your written request to Secretary, ARCA biopharma, Inc.,
11080 CirclePoint Road, Suite 140, Westminster, Colorado, 80020 or contact Investor Relations at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">720-940-2100.</FONT></FONT> The Company undertakes to promptly deliver a separate copy
of the Notice of Internet Availability of Proxy Materials promptly upon receiving your written request. Stockholders who currently receive multiple copies of the Notices of Internet Availability of Proxy Materials at their addresses and would like
to request &#147;householding&#148; of their communications should contact their brokers. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>O<SMALL>THER</SMALL> M<SMALL>ATTERS</SMALL>
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Board of Directors knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters
are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">By Order of the Board of Directors</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g521080snap1.jpg" ALT="LOGO">
</P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Christopher Ozeroff</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Secretary,&nbsp;Senior&nbsp;Vice&nbsp;President&nbsp;and&nbsp;General&nbsp;Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;18, 2018 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A copy
of the Company&#146;s Annual Report to the Securities and Exchange Commission on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, is available without charge upon written request to: Corporate
Secretary, ARCA biopharma, Inc., 11080 CirclePoint Road, Suite 140, Westminster, Colorado 80020 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="6">


<IMG SRC="g521080dsp01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">


<IMG SRC="g521080dsp01a.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Arial Narrow" SIZE="3"><B>Electronic Voting
Instructions</B></FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>Available 24 hours a day, 7 days a week!</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Arial Narrow" SIZE="1">Instead of mailing your proxy, you may choose one of the voting methods outlined below to vote your proxy.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Arial Narrow" SIZE="1">VALIDATION DETAILS ARE LOCATED
BELOW IN THE TITLE BAR.</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Proxies submitted by the
Internet or telephone must be received by 1:00 a.m., Mountain Time, on May 31, 2018.</B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="4">


<IMG SRC="g521080dsp01c.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>Vote by Internet</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Arial Narrow" SIZE="1">&#149; Go to <B>www.investorvote.com/ABIO</B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Arial Narrow" SIZE="1">&#149; Or scan the QR code with your smartphone</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Arial Narrow" SIZE="1">&#149; Follow the steps outlined on the secure website</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>Vote by telephone</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:0.63em; text-indent:-0.63em"><FONT STYLE="font-family:Arial Narrow" SIZE="1">&#149;&#8201;&nbsp;&nbsp;Call toll free 1-800-652-VOTE (8683) within the USA, US
territories &amp; Canada on a touch tone telephone</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:0.63em; text-indent:-0.63em"><FONT
STYLE="font-family:Arial Narrow" SIZE="1">&#149;&#8201;&nbsp;&nbsp;Follow the instructions provided by the recorded message</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Arial Narrow" SIZE="1">Using a <B><U>black ink</U></B> pen, mark your votes with an <B>X</B> as shown in this example. Please do not write outside the designated areas.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9746;</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT>
<FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g521080dsp01b.jpg" ALT="LOGO">
 </P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT
STYLE="font-family:Arial Narrow" SIZE="1"></FONT><B>&nbsp;IF YOU HAVE NOT VOTED VIA THE INTERNET <U>OR</U> TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.</B>&nbsp;<FONT
STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT> </FONT></P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt dashed #ff00ff">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle" NOWRAP ALIGN="center" BGCOLOR="#000000"><FONT STYLE="font-family:Arial Narrow" SIZE="1" COLOR="#FFFFFF"><B>&nbsp;A&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#ffffff"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP BGCOLOR="#ffffff"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>Proposals&nbsp;&#151;&nbsp;The Board of Directors recommends a vote <U>FOR</U> the nominees listed and <U>FOR</U> Proposal
2.</B></FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" COLSPAN="15"><FONT STYLE="font-family:Arial Narrow" SIZE="1">1. Election of two directors to hold office until the 2021 Annual Meeting of Stockholders.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="right"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B><FONT STYLE="font-family:Arial Narrow" SIZE="6">+</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Withhold</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Withhold</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle" COLSPAN="3" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;01&nbsp;-&nbsp;Raymond&nbsp;L.&nbsp;Woosley</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;
</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;
</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;02&nbsp;-&nbsp;Daniel&nbsp;J.&nbsp;Mitchell</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;
</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;
</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Against</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Abstain</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Arial Narrow" SIZE="1">2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Arial Narrow" SIZE="1">To ratify the selection of KPMG LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December 31, 2018.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Arial Narrow" SIZE="1">In their discretion, the proxies are also authorized to vote upon such other matters as may properly come
before the Annual Meeting. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle" ALIGN="center" BGCOLOR="#000000"><FONT STYLE="font-family:Arial Narrow" SIZE="1" COLOR="#FFFFFF"><B>&nbsp;B&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Voting</FONT> Items</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Change of Address </B>&#151; Please print your new address below.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Comments</B> &#151; Please print your comments below.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Meeting&nbsp;Attendance</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Arial Narrow" SIZE="1">Mark the box to the right</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" ROWSPAN="2" ALIGN="right"><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;</FONT><FONT
STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:2px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Arial Narrow" SIZE="1">if you plan to attend the</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:2px solid #000000; BORDER-BOTTOM:2px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Arial Narrow" SIZE="1">Annual Meeting.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px;page-break-before:always"></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle" BGCOLOR="#000000"><FONT STYLE="font-family:Arial Narrow" SIZE="1" COLOR="#FFFFFF"><B>&nbsp;C&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>Authorized Signatures &#151; This section must be completed for your vote to be counted. &#151; Date and Sign Below</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="10"><FONT STYLE="font-family:Arial Narrow" SIZE="1">Please date and sign exactly as the name appears on this card. Joint owners should each sign. Please give full title when signing as executor, administrator, trustee,
attorney, guardian for a minor, etc. Signatures for corporations and partnerships should be in the corporate or firm name by a duly authorized person.</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Arial Narrow" SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1">Date (mm/dd/yyyy) &#151; Please print date below.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1">Signature 1 &#151; Please keep signature within the box.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1">Signature 2 &#151; Please keep signature within the box.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER:2px solid #000000; padding-left:8px"><FONT STYLE="font-family:Arial Narrow" SIZE="5">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="justify">


<IMG SRC="g521080dsp01d.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:42px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Arial Narrow" SIZE="4"><B>Important notice regarding the Internet availability of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>proxy materials for
the Annual Meeting of Stockholders. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>The ARCA biopharma, Inc. Annual Report </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>and ARCA biopharma, Inc. Notice of Annual Meeting are available at: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>www.edocumentview.com/ABIO </B></FONT></P> <P STYLE="margin-top:120px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Arial Narrow" SIZE="1"><B></B><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B></B></FONT><B>&nbsp;IF YOU HAVE NOT
VOTED VIA THE INTERNET <U>OR</U> TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED
ENVELOPE.&nbsp;</B><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B></B></FONT><B> </B></FONT></P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt dashed #ff00ff">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g521080dsp02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="3"><B>Proxy &#151; ARCA BIOPHARMA, INC.</B> </FONT></P> <P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>PROXY SOLICITED BY THE BOARD OF DIRECTORS OF ARCA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Arial Narrow" SIZE="4"><B>FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 31, 2018 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Arial Narrow" SIZE="2">The
undersigned hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy Statement of ARCA biopharma, Inc. (the &#147;Company&#148;) in connection with the Company&#146;s Annual Meeting of Stockholders to be held at the
Renaissance Boulder Flatiron Hotel, 500 Flatiron Blvd., Broomfield, Colorado 80021 at 9:00 a.m., Mountain Time, on Thursday, May 31, 2018, and does hereby appoint Michael R. Bristow, M.D., Ph.D., Thomas A. Keuer and Christopher D. Ozeroff, and each
of them (with full power to act alone), as proxies of the undersigned with all the powers the undersigned would possess if personally present and with full power of substitution in each of them, to appear and vote all shares of Common Stock of the
Company which the undersigned would be entitled to vote if personally present at the 2018 Annual Meeting of Stockholders, and at any postponement or adjournment thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Arial Narrow" SIZE="2">The shares represented hereby will be voted as directed herein. <B>IN EACH CASE, IF NO DIRECTION IS INDICATED, SUCH SHARES WILL BE VOTED &#147;FOR&#148; THE NOMINEES LISTED AND &#147;FOR&#148; PROPOSAL 2. AS
TO ANY OTHER MATTER THAT MAY PROPERLY COME BEFORE THE MEETING OR ANY POSTPONEMENT OR ADJOURNMENT THEREOF, SAID PROXY HOLDERS WILL VOTE IN ACCORDANCE WITH THEIR BEST JUDGMENT. THIS PROXY MAY BE REVOKED IN WRITING AT ANY TIME PRIOR TO THE VOTING
THEREOF.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>PLEASE VOTE, DATE AND SIGN ON THE REVERSE SIDE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>Please be sure to sign and date this Proxy.</B> </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center">


<IMG SRC="g521080dsp03.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g521080dsp03c.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g521080dsp003aa.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top">


<IMG SRC="g521080dsp03b.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="163"></TD>
<TD HEIGHT="163" COLSPAN="2"></TD>
<TD HEIGHT="163" COLSPAN="2"></TD>
<TD HEIGHT="163" COLSPAN="2"></TD>
<TD HEIGHT="163" COLSPAN="2"></TD>
<TD HEIGHT="163" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Arial Narrow" SIZE="1">Using a <B><U>black ink</U></B> pen, mark your votes with an <B>X</B> as shown in this example. Please do not write outside the designated areas.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9746;</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT
STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g521080g49g15.jpg" ALT="LOGO">
 </P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT
STYLE="font-family:Arial Narrow" SIZE="1"></FONT><B>&nbsp;PLEASE FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.</B>&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT
STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT> </FONT></P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt dashed #ff00ff">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle" ALIGN="center" BGCOLOR="#000000"><FONT STYLE="font-family:Arial Narrow" SIZE="2" COLOR="#FFFFFF"><B>&nbsp;A&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#ffffff"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" BGCOLOR="#ffffff"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>Proposals&nbsp;&#151;&nbsp;The Board of Directors recommends a vote <U>FOR</U> the nominees listed and <U>FOR</U> Proposal
2.</B></FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" COLSPAN="15"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Arial Narrow" SIZE="1">1.&#8201;Election of two directors to hold office until the 2021 Annual Meeting of Stockholders.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="right"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B><FONT STYLE="font-family:Arial Narrow" SIZE="6">+</FONT></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD COLSPAN="3" VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Withhold</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Withhold</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle" COLSPAN="3" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;01&nbsp;-&nbsp;Raymond&nbsp;L.&nbsp;Woosley</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;
</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;
</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;02&nbsp;-&nbsp;Daniel&nbsp;J.&nbsp;Mitchell</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;
</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;
</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="2"></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="54%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>For</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Against</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B>Abstain</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Arial Narrow" SIZE="1">2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Arial Narrow" SIZE="1">To ratify the selection of KPMG LLP as the Company&#146;s independent registered public accounting firm for the fiscal year ending December
31, 2018.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="5"><FONT STYLE="font-family:Times New Roman" SIZE="5">&#9744;</FONT><FONT STYLE="font-family:Arial Narrow" SIZE="5"></FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Arial Narrow" SIZE="1">In their discretion, the proxies are
also authorized to vote upon such other matters as may properly come before the Annual Meeting. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="middle" BGCOLOR="#000000"><FONT STYLE="font-family:Arial Narrow" SIZE="2" COLOR="#FFFFFF"><B>&nbsp;B&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="middle"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>Authorized Signatures &#151; This section must be completed for your vote to be counted. &#151; Date and Sign Below</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="11"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="10"><FONT STYLE="font-family:Arial Narrow" SIZE="1">Please date and sign exactly as the name appears on this card. Joint owners should each sign. Please give full title when signing as executor, administrator, trustee,
attorney, guardian for a minor, etc. Signatures for corporations and partnerships should be in the corporate or firm name by a duly authorized person.</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Arial Narrow" SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1">Date (mm/dd/yyyy) &#151; Please print date below.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1">Signature 1 &#151; Please keep signature within the box.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Arial Narrow" SIZE="1">Signature 2 &#151; Please keep signature within the box.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER:2px solid #000000; padding-left:8px"><FONT STYLE="font-family:Arial Narrow" SIZE="5">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:2px solid #000000; BORDER-TOP:2px solid #000000; BORDER-BOTTOM:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-RIGHT:2px solid #000000; BORDER-BOTTOM:2px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g521080bottom.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:42px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Arial Narrow" SIZE="4"><B>Important notice regarding the Internet availability of </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>proxy materials for
the Annual Meeting of Stockholders. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>The ARCA biopharma, Inc. Annual Report </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>and ARCA biopharma, Inc. Notice of Annual Meeting are available at: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>www.edocumentview.com/ABIO </B></FONT></P> <P STYLE="margin-top:120px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Arial Narrow" SIZE="1"><B></B><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B></B></FONT><B>&nbsp;PLEASE FOLD ALONG
THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED
ENVELOPE.&nbsp;</B><FONT STYLE="font-family:Times New Roman" SIZE="1"><FONT STYLE="FONT-FAMILY:'WINGDINGS 3'">&#113;</FONT></FONT><FONT STYLE="font-family:Arial Narrow" SIZE="1"><B></B></FONT><B> </B></FONT></P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt dashed #ff00ff">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g521080page_040.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:2px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="3"><B>Proxy &#151; ARCA BIOPHARMA, INC.</B> </FONT></P> <P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="4"><B>PROXY SOLICITED BY THE BOARD OF DIRECTORS OF ARCA BIOPHARMA, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Arial Narrow" SIZE="4"><B>FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 31, 2018 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT STYLE="font-family:Arial Narrow" SIZE="2">The
undersigned hereby acknowledges receipt of the Notice of Annual Meeting of Stockholders and Proxy Statement of ARCA biopharma, Inc. (the &#147;Company&#148;) in connection with the Company&#146;s Annual Meeting of Stockholders to be held at the
Renaissance Boulder Flatiron Hotel, 500 Flatiron Blvd., Broomfield, Colorado 80021 at 9:00 a.m., Mountain Time, on Thursday, May 31, 2018, and does hereby appoint Michael R. Bristow, M.D., Ph.D., Thomas A. Keuer and Christopher D. Ozeroff, and each
of them (with full power to act alone), as proxies of the undersigned with all the powers the undersigned would possess if personally present and with full power of substitution in each of them, to appear and vote all shares of Common Stock of the
Company which the undersigned would be entitled to vote if personally present at the 2018 Annual Meeting of Stockholders, and at any postponement or adjournment thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="justify"><FONT
STYLE="font-family:Arial Narrow" SIZE="2">The shares represented hereby will be voted as directed herein. <B>IN EACH CASE, IF NO DIRECTION IS INDICATED, SUCH SHARES WILL BE VOTED &#147;FOR&#148; THE NOMINEES LISTED AND &#147;FOR&#148; PROPOSAL 2. AS
TO ANY OTHER MATTER THAT MAY PROPERLY COME BEFORE THE MEETING OR ANY POSTPONEMENT OR ADJOURNMENT THEREOF, SAID PROXY HOLDERS WILL VOTE IN ACCORDANCE WITH THEIR BEST JUDGMENT. THIS PROXY MAY BE REVOKED IN WRITING AT ANY TIME PRIOR TO THE VOTING
THEREOF.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>PLEASE VOTE, DATE AND SIGN ON THE REVERSE SIDE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="2"><B>Please be sure to sign and date this Proxy.</B> </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g521080bottom.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080bottom.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( #X#4@,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * .5\?>,O^$'T*#4_L'VWS;E8/+\WR\95
MFSG!_N]/>@#SK_AH?_J5_P#R?_\ M= [!_PT/_U*_P#Y/_\ VN@+'J?@_P 1
M?\)7X6LM;^R_9?M._P#<^9OV[79>N!G[N>G>@1N4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M"&F1!((RZAR,A<\D4#L[7'4"(Y;B&$J)9DC+<+N8#-!482E\*)*"0H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M  7ZQ_47Q=_R-G@W_K^D_P#134J?\;_MU_H*?\)^L3>\0_\ (M:I_P!>LO\
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M.XH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#(T#1/["@O8_M'G_:KR6ZSLV[=YSMZG./6A
M:0C'LK?BP>LY2[_Y)?H1^)/#YUV&T>"\:RO[*83VUPJ!]C8(.5/4$'D4M5)2
M7])CT<7%[?Y%"Q\,:I-KMIJWB#6([Z2R#?9H8+;R8T9A@L?F)8XX]JJ+4;M;
MO3Y$N[7+TW.AU"T^W:;=6>_9Y\31[L9VY!&<?C6<X\\7$N$N22EV(-#TS^Q=
M!L-,\[SOLD"0^9MV[MHQG&3C\ZVJ3YY.1G&/*K#==TZZU72)K&TOS8/,-K3*
MFY@G\07D8)'&>U9.*E9/;KYFD9<NJW,O4O!EI-I>F6VER_V;<Z4RM9W")O,>
M/O C(W!AU&>:TYG[3G_JW;_+L0DE!P?]/N=*NX* Q!;') P*D%YBT#"@ H I
MZI8?VGI\EKY\D#-@K+&<,C Y!]^G3O33LTS?#UO8U%.U_)F?:Z+>OJL&HZK?
M1W,MJC) D,/EJNX %CDG)('TJ^9)-16YT5,335)TJ$;*5KW=WILMEH;E9G 9
MT6E>7XAN-6:;<9($@6/;]P DGG/.2?3M5*5H\OG<Z98B^'C02V;?K?\ R-&I
M.8S-4TVZNI[:[L;XVMU;Y WJ7C=3U#+D9]CGBJB[7N=>'KPA&4*L;Q?R:]'9
MB:1I#Z?+=75S<?:;Z[8--*$V+@#"JHR< ?7O3E)-**V08G$*JHP@K1CLM_5O
MS-2H.0SM/TK[#J&I7C3>:][*K_=QL 4*%Z\]#^=5S>ZH]KG36Q'M:=."5E%6
M_&]S1J3F,C4-+OWU$7^F:B+:4Q^5)'-&9(V&<@X####UJHM)--';1KTE3]E6
MA=7NFG9_D]"?1]*72+1XO-::::5III6&"[MU..W88]J)2O9+9&>)Q#Q$U*UD
MDDEV2+=Q;07D#07,$<\+?>CD4,I^H-2G9W1C"I.G+F@[/NC&7PCI46NVVI06
M5I"L$;*(DME +$@A\CH1CT[UJJLK--[G<\QKRH2HRDW=[W>VNGHS>K(\XYFY
M\-ZI)XAFU>#6HHW90D22V?F>2O<*=XZ]SBM(SBH\K1ZL,;06'5"5-V6KM*UW
MYZ?<;]E'<PVD:7=PMQ.,[I%CV!N?[N3C\ZAVOH>=5E"4VX*R[7O^)/2,PH *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@".:"*Y@D@
MGB26&12KHZAE8'J"#U%)I/<:;3NB.RT^RTRV%M86D%I "2(X(PB@GKP.*J[9
M-K%BD,* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MT*D84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
8% !0 4 % !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g521080dsp003aa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp003aa.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MU]^T!XO^%/QY^%EUHVL^)(_ 7@"PTW5OB3X9\/23E?%5UX_N_$&F>$-(O;:
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G0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g521080dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /?Z "@ H * "@ H * "@"O<W]K9\3SJA].I_*@"M_;VF_\
M/S_XXW^% !_;NF_\_/\ XXW^%  -=TTG N?S1O\ "@"]%+'-&'B=70]U.: '
MT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M:EF8] !R30!Y?\,/B%<>*O$FNV=Y+E&?[19(>"D8.TK^ VGZDT#/4Z!!0 4
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M1YA.(QCT !QZ;10,^B*!!0!FG1+,^(TUT*RWJVQM21C#(6#<\=01Q]30!I4
M<7\2;R:31[3P[9L1>:[<+:*5ZK%UD;Z!>#]: /*==@3X:_&>TO+9?)TZ0I(%
M' \IQL<>^#N/Y4#/HD$,H*D$'D$4"%H * "@ H * "@ H * "@ H * "@ H
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MSONN+8?9IN<G<G )^J[3^- CL: "@ H * "@ H * "@ H * "@ H * "@ H
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MS,\9]* )J "@! REBH8$CJ,]* $<E48@ D#(!.* *>E7LM_;-.\:QJ6P@'/
M]Z +U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MSR(BYV*.Q/O0!L4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M\S>Q]!_@* -:@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M.:<FYOF>XH^[HBM9CPI92P31:9K#3PRF99I=-OI'+E2NYF9"6.TD<YQVHO\
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MW)?);!_PY);Q>%+343?P6.OI<%Q(Q%IJ.UV  !9=N&X ZBFG;;S_ !W$U?\
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M&A0VL@W8E73YHBO!_B9 !^=*3GRN[_$YL7.JZ+4JKDNW-%_@FV=C6!X@4 %
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MQZE034'))6;1SFLZK>VEWK:03;%MM(^TQ#:#MDS)\W(Y^Z.#QQ6L(I\M^_\
MD>IA</3J0I.2^*=GZ>[I^+)-,U.\N/$,5K+-NA;2HK@KM _>,S G./0#CI2<
M4HW\R*]"G##N<5KSM?))'0UF>:<AJ&MZC!\4-)T>.XVV$]JTDD6Q3N;$G.<9
M'W1W[5T1A%T7+K_PQ[='"T9994Q#7O)V3U_N_+JSKZYSQ H * "@ H * "@
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MK Y%3.,5%VM]YQ9A2IQP\G%0Z?#)M[]FCT2N4^9"@ H * "@ H * "@ H *
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MG:>29VWX'G6_DD<>G<>]-JQCB(QC*T4OD[FA4G.% !0 4 % !0 4 % !0 4
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M/[Z-^F*NFFV[*YZV70J24N2'-M_-^DD<U]NTK_H/Q?\ ?ZU_^,5MRR_E_/\
MS/4]C7_Y\O[I_P#R9J>'KO3Y=;@2#5H[B0[L1B2 D_*>RQ*?UJ9*2B_=M]_^
M9QXVG5C1;E3LM-;2[^<FOP.XK \$* "@ H * "@"A=Z;IUQ%=6]S&K+>?-*K
M2$%MH R.<C&!TQ3O;Y'13KUH.,H/X=M._P#74I+I&AK9-B9C#E1YIO9"R[?N
M@/NR,>@-4YRO<W>(Q+GMKKIRKKOI:S^XU+2WMK.T"6^!",MN+ELYY)+$Y/U)
MJ9.^YR5)SJ3O+?\ KH.M(H(;2**UQY"J F&R,?6AWZBJ2E*;<]R:D0% !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 <OXNLYKM[3RM5MK':&SYUFD^_ITW XQ_6M*<E%NZN>MEU6--2
MYJ;EMM)QM]VYS7]CW?\ T-.G?^"B+_XFM?:0_E_$]7ZS3_Y\2_\ !DO\S4\.
MZ;<6^MP22:]97:@-^ZBTZ.)C\IZ,!D4I3BXM*/XG'C:\)T&E2<=M7-OKV;.Y
MKG/ "@ H * "@ H Y+Q!#?RZA-J%O9O*EBHC0+NWN&!\S:N/G&&7OU6JC\+7
M?^EZ:_@>S@Y4HTU2E*W-KTMIM=WTV?R95\J)ELYXM-N$M84A6Y7[%("[!A_!
MMRV.>0.]:/XWKUTU\G_P#2\ES1<US.]O>6B];V5_7H:\"I#H-_))83/:M*TD
M5JL3!RO&!L R,G)QCOTK-WT77_@_H<<KRKP2DN:R3=U:_KMMI<NZ"BII:E0Z
MEW=V5H6BVL6)("L 0.?3GK3GH[&&+;=77I9;I[+NFT:=0<H4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0!RWB^^L[-[,7<MPFX-M\DSC/3KY3#]:TIW;=OT_4]?+:52HI<B73?E_\
M;D_P.9_MO1_^?F__ .^[W_XY6MI^7X'J_5<1_+'_ ,I__(FIX<U33KC7((K>
M>[:4AL"1KHK]T_WW*_F*4E+E=[?@<>-H5H4'*:5M-N3OY),[NN<^?"@ H *
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M%MQC8<<<C/?DFJ4FMCMHXVK1Y>79=-;._?4C'AM!$H;4KQYH]@BG/E[HPIR
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M7<I,I&YL,>3BG/=6[+\C+')*O*UOEL:U0<84 % !0 4 % !0 4 % !0 4 %
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M7DDD:1RJ[1ECG@<\4-]$9UJBJ2NE9))?<6Z1B% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <[XGBM
M9&M?M.EQWV VW?:23[.G]Q3C\?2KI\UWRNWSL>G@)5(J7)/EV^TH_FT<_P#9
M=+_Z%>W_ /!3<?\ QNM;S_F_%?YGH^TK_P#/]_\ @</_ )(T="@L(]7A:#0H
M;60;L2KI\T17@_Q,@ _.E)SY7=_B<V+G5=%J55R7;FB_P3;.QK \0* "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* ()+.UECFCDMHG2?F560$2< ?,._  Y]*=V:*K.+34G=;>7H5UT/2$M7M5T
MNS6W<AFB$"A6(Z$C&#3<Y-WN:O%XAR4W-W76[N65M+:.T^R);Q+;;=OE! $Q
MZ8Z8I-MN[,74FY\[;OWZCH((;6%88(DBB7HJ# %#;>XI3E-\TG=DE(D* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
+"@ H * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g521080dsp01a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp01a.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M,J1ST]:<:;DDUUO^!O#+:LX1FFK--_*._0NQZ];R7:VXCE#L5&<#'S,ZCO\
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MO6/Z'L8W>K_CC_Z2=!>_\@/Q#_U[7?\ Z/DKF6\?^W#SJ7^\4/6'_I,3!/\
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M1_\ L$S_ /HXUU5?CEZQ_0]C&[U?\<?_ $D]@KA/BPH * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M#?7F_ [*."H2HTY..KA-O?=;&U!JMZ^JQPM.3&3'D;1W>8'MZ(OY5DDN5/\
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M0^!_+\IF)K'_ ",&M_\ 86L?_036E+X8?]O'HX?_ '>E_P!>ZAT5M_R&X?\
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M5=P7.WR<[?+&-N=W.<]>U7"IRJ*MM?\ $Z*>9\E.,.3X8RCO_-UVZ&C%X?\
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MET&W?@[[3X=DTG[?MWB$>9Y6<>6 .F>^/7BJC5M44[=;E4\RY,0J_+_-I?\
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MV#GC&<CCFJM&_K_D7+"4H-TVW=\UGZ;:>9;T[4KV>]@,_E&VNUD:-54AH]K
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ME9:Z?A_6I/UV*LXQU;5]=[*VFFE[Z[CAH=^";P7\(U,RES)Y!\K&P)MV;L]
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M*G[?D6VVMKW:OOV7?<@AU34;FU%\;O8;80*T:A=DI8@.3WY!XP>*KW;[;O\
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M_P#3+>-DY)\JMK=:V=][ZW^ZUN@V+PM;0R*RW5SAG$EPI*XN'#;@S<=<G^'
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M'AJU+3"2XGDB='2.(D 0ASEMN!GJ!U)QCBCFLDEY?AL:?79Z623T;?>VBO\
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$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g521080dsp01b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp01b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M?_QR@+!_POSPK_SX:M_WYC_^.4!8/^%^>%?^?#5O^_,?_P <H"P?\+\\*_\
M/AJW_?F/_P".4!8/^%^>%?\ GPU;_OS'_P#'* L'_"_/"O\ SX:M_P!^8_\
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M_P#'* L'_"_/"O\ SX:M_P!^8_\ XY0%@_X7YX5_Y\-6_P"_,?\ \<H"P?\
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M/"O_ #X:M_WYC_\ CE 6#_A?GA7_ )\-6_[\Q_\ QR@+!_POSPK_ ,^&K?\
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MO_/AJW_?F/\ ^.4!8/\ A?GA7_GPU;_OS'_\<H"P?\+\\*_\^&K?]^8__CE
M6#_A?GA7_GPU;_OS'_\ '* L'_"_/"O_ #X:M_WYC_\ CE 6/2M,OXM5TFSU
M&!76&[A2=%< ,%90PSC/.#0(HZ[I&F:K]G_M'3K6\\O=L\^%9-N<9QD<=!^5
M &-_PB/AK_H7M+_\ X_\* #_ (1'PU_T+VE_^ <?^% !_P (CX:_Z%[2_P#P
M#C_PH /^$1\-?]"]I?\ X!Q_X4 '_"(^&O\ H7M+_P# ./\ PH /^$1\-?\
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M_A$?#7_0O:7_ . <?^% !_PB/AK_ *%[2_\ P#C_ ,* #_A$?#7_ $+VE_\
M@''_ (4 '_"(^&O^A>TO_P  X_\ "@ _X1'PU_T+VE_^ <?^% !_PB/AK_H7
MM+_\ X_\* #_ (1'PU_T+VE_^ <?^% !_P (CX:_Z%[2_P#P#C_PH /^$1\-
M?]"]I?\ X!Q_X4 '_"(^&O\ H7M+_P# ./\ PH /^$1\-?\ 0O:7_P" <?\
MA0 ?\(CX:_Z%[2__  #C_P * #_A$?#7_0O:7_X!Q_X4 '_"(^&O^A>TO_P#
MC_PH /\ A$?#7_0O:7_X!Q_X4 '_  B/AK_H7M+_ / ./_"@ _X1'PU_T+VE
M_P#@''_A0 ?\(CX:_P"A>TO_ , X_P#"@ _X1'PU_P!"]I?_ (!Q_P"% !_P
MB/AK_H7M+_\  ./_  H /^$1\-?]"]I?_@''_A0 ?\(CX:_Z%[2__ ./_"@
M_P"$1\-?]"]I?_@''_A0 ?\ "(^&O^A>TO\ \ X_\* #_A$?#7_0O:7_ . <
M?^% !_PB/AK_ *%[2_\ P#C_ ,* #_A$?#7_ $+VE_\ @''_ (4 '_"(^&O^
MA>TO_P  X_\ "@ _X1'PU_T+VE_^ <?^% &1K=AX5T<P0)X6L+S4+DD6]I#9
MQ;Y,=3DC"J.Y- %-?"%],-YT#PC:9_Y9-IYF(^K#;_*@!?\ A"[W_H&>$/\
MP3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\
MA"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\
MP3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\
MA"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\
MP3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\
MA"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\
MP3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\ A"[W_H&>$/\ P3G_ .+H /\
MA#+X<_V5X0/M_9)&?QWT .L+'0TU&/2]=\(:58WDN?(DCMXW@N,=0K;00W^R
M0#]: .@_X1'PU_T+VE_^ <?^% !_PB/AK_H7M+_\ X_\* #_ (1'PU_T+VE_
M^ <?^% !_P (CX:_Z%[2_P#P#C_PH /^$1\-?]"]I?\ X!Q_X4 '_"(^&O\
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M%OI;S%%IQ4^G7R+T7BR[M-2>SUFSBM673?MP9')''WDY[BE)J,9M?9M\[_\
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MZ L'_"^/^I;_ /)W_P"UT!8/^%\?]2W_ .3O_P!KH"P?\+X_ZEO_ ,G?_M=
M6#_A?'_4M_\ D[_]KH"P?\+X_P"I;_\ )W_[70%@_P"%\?\ 4M_^3O\ ]KH"
MP?\ "^/^I;_\G?\ [70%@_X7Q_U+?_D[_P#:Z L'_"^/^I;_ /)W_P"UT!8B
MN/C?;W<1BN?"D<T?79)=AA^1CH#8=%\<XX(EBA\+K'&HPJI>8 _#RZ=[BM8?
M_P +X_ZEO_R=_P#M=(=@_P"%\?\ 4M_^3O\ ]KH"P?\ "^/^I;_\G?\ [70%
M@_X7Q_U+?_D[_P#:Z L0_P#"[K<W(N3X4C^T!=HE^U#=CTSY><4;!:Y-_P +
MX_ZEO_R=_P#M= 6#_A?'_4M_^3O_ -KH"P?\+X_ZEO\ \G?_ +70%@_X7Q_U
M+?\ Y.__ &N@+!_POC_J6_\ R=_^UT!8/^%\?]2W_P"3O_VN@+!_POC_ *EO
M_P G?_M= 6#_ (7Q_P!2W_Y._P#VN@+!_P +X_ZEO_R=_P#M= 6#_A?'_4M_
M^3O_ -KH"P?\+X_ZEO\ \G?_ +70%@_X7Q_U+?\ Y.__ &N@+!_POC_J6_\
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M+IG_ $!-4_\ "@G_ ,* L'_"Q=,_Z FJ?^%!/_A0%@_X6+IG_0$U3_PH)_\
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M_2@#6TWXQ:?H]O\ 9].\'Q6T1.2([O&3ZD^7R?<T!8N_\+X_ZEO_ ,G?_M=
M6#_A?'_4M_\ D[_]KH"P?\+X_P"I;_\ )W_[70%@_P"%\?\ 4M_^3O\ ]KH"
MP?\ "^/^I;_\G?\ [70%@_X7Q_U+?_D[_P#:Z L'_"^/^I;_ /)W_P"UT!8]
MLT*__M7P_INH^5Y7VJUCFV;MVW<H.,]\9H$7Z "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
, "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g521080dsp01c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp01c.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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E6;%A<1W$;!AEF3.-V1R.>>E).QA1Q4Z+FXI>\FGZ/L:5(Y3_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g521080dsp01d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp01d.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MGCFFU%I\O0<Z-"I1E4I)KE:6KO>_R5GY:D<.K:M!JUA;WWV0F]9@UI$#YMN
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M<>DRFT=;JX-QY-M( #YH R3@<' ##C^[3MM?Y_UYZ?>:0P]-U5SZ*UWY=/\
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M=;O>OEK$\F\Y&=VX9(QC\:46KQDWM;\-B(XBC[6.+<M4E[NM[I6[6MUW.R'
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M9_Y"EA/B9S\-?Q:GHCGO%/\ R37PM_P*M*7\:1Z67_\ (RQ'R-5O^0#\/?\
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M_P#O=7_%+\V:M0<84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MM)1U7D[VM8C;0].EG::2?S8Y&,YC81E6![D[<D<^M%[*Q2Q56,>5*S6E]?\
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M_P"2:^*?^ T5?XT0S#_D98?YG0Z)_P CMX6_[%^+^35G4^"7^(\W%?[EB/\
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MQ._Y$0?]=8_ZUAA_XB/#R'_?ODSI/#'_ "*>C?\ 7E#_ .@"LJGQOU/+Q_\
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M:S>';V[E@5YX82(W89V9(SCT^M72;52-NZ_,]+*ZLXXB--/1O4Z,=!69Y8M
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MAG+85%1BF1*0<G&-NWH3VQBG9)Z>7]>I4H48IJ+37RO\*MYWOVZ[G4UF>2%
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M19+;(D"KDG).!ZFC=6#K<6TL[6PMUM[.VBMX%)(CB0(HR<G@>]%PZW)J "@
MH J7VE:?J6S[=907/EG*^;&&Q],TXR<7=&U+$5:-_92:OV=BTJJBA44*JC
M& !2,FVW=C)H(;F%H9XDEB;JCJ&!_ T+1W0XSE!\T79DE!(R6*.:)HI45XV&
M&5AD$>A% XR<7>+LR"QTVQTR-H[&SAMD8Y81(%R??%4Y.6[-*M>K6=ZDFWYL
MM5)D1PP0VT0B@B2*->B(H4#OT%-NY4IRF^:3NR2D24FTC36U 7[6%N;P=)C$
M-X_'K5*32LGH;K$5E3]ESOE[7T+M28$<T$-Q'Y<\22ID-M=01D'(//H1FA.S
MNBHSE!WB[$E!)'-!%<0M#/$DL3##(Z@@_4&A::HJ,I0?-%V9)02% !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '(^+
M/!TWB/7_  ]J4=XD"Z3/YS(R$F3YE.!Z?=_6G3?)4Y_*WY_YCD^:FX'74A!0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M]Z-UY?CJAO1\OK^&C-:@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
)4 % !0 4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g521080dsp02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp02.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /?Z *-WJUG9/LEDR_\ =49(H K?\))8^DO_ 'S_ /7H /\
MA([+^[+_ -\__7H /^$DL<])1_P'_P"O0!H6MY;WL>^"0.!U'0C\* )Z "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * *NI7+6FG33+]Y1Q]2<?UH
M X=5:5R2223DD]Z8B[!9EP0!R!G% %@V!*Q;5Y?I^= %2:UP3CD#O0 VPN'L
M;^*120,X8>H[T =U2&% %#6]5@T+1+W5+G_56L32$>N!P/J3@?C0!YE\%/&%
MUK9UC3]2N#+=>:;N,LV3M8X8#/8''_?5 SUR@12U;31JVG26;7=W:!\?O;28
MQ2+@]F% '@/Q$U7Q7X)\3+IEOXKU&>WD@6:-I7^8 DC!(Z\J>>*!GJ4/P]OF
MBCEN?&_B,W@4;C'=A8]W^YM/'XT".+/C[Q%\/O&QT+Q->#5-,8J5N&0+(L;=
M'&.N.<@YZ<&@9[8"" 0<@]"*!' ?$'XF0>$G33-.@%[K<P&R+!*QYZ;L<DGL
MH_3C(!%HO@SQ!K4*:AXSU^^,TGS#3[.8P11 ]FV8R1^GJ: +M[\+]+DM633-
M2U73+CJLL-](W/N&8Y_2@##^'3^)-&\<:MX:\1ZE<WI2V$]L\TK.'0,!N4G_
M 'AQVQ0,]4H$1W$\5K;2W$SA(HD+NQZ  9)H \=^%OCZXUWQ[K=M>3/Y6HDS
MVL;M_J]O\ '^YC_OF@9[-0(* ,[7?^0-<?\  ?\ T(4 <S:1*Q )Q[XIB-O<
MEG%&[@-+G"%3PP]_I2&6+<R21@F-  "!@=,T 5[RV4(-I5(^HSU8T 84J!9E
MQ_>%,1W-(84 <)XWD_MOQ#H/A"/YDN)1>WH':",Y /LS#'X4 >9W;#X>?'83
M#]U874H<\X'E2]?P5LG_ (#0,^AZ!!0!\Z?'S_D>K'_L')_Z,DH&CZ+H$?._
MQ7MYO%GQ6M])T=/M%U';1V[A>BMN9B2>P 89/:@9[O>74>@^'9[J8[H[&V+M
M[A%S_2@1X/\ "*QE\5_$:\U_4R)Y+8&X);_GJQPO'H!NQZ8% SZ)H$% %233
M;2358=3:'-Y#$T*29(PC$$C'0\J.M %N@#B/B3=RSZ;8>&;1RMWKMPMME<92
M$<RM^"\?C0!Y?\0;+_A /BEIFN6,92T<1RJB_P"P CH/JH'_ 'U0,^@X)H[F
MWCGA8/%(H=&'0@C(- B2@#.UW_D#3_\  ?\ T(4 8%BWS "-6/O3$7-25@D$
MRA"J9#B/HN>E R:VU$)%@&D(L3$_9U!6-GQDJ?O"@9@3L#,OR@?-3$=K2&(2
M%4DD #DD]J /)?"U[XAUGQ1KGC#3-(M;VVNG^R6CSW1B*11G^'Y3PQP?J#0,
MY_XR:;X@O["RUK4]&M;-;4F%I(+HS$AN1D%1@ @_]]4 CU/X>:]_PD?@?3;Y
MFW3K'Y,V>N]."?QP#^- CJ* /G3X^?\ (]6/_8.3_P!&24#1UOQ&TGQCX?T"
M74M+\5ZC=6B<7$;A5D13QN#(!QZ^G6@"_P#!:]T.^\.R&TLXH-8A.V]<G=)+
MDY#ECS@^G0'- '7^.H)+GP'KL40)<V4I 49)PI./TH$>3_L^3(NI:[ 3^\>*
M)P/8%@?_ $(4#9[Q0(* "@ H \IAO-:U_P"*&I:UI&G6]_::,AT^#S[GRE$A
MY=A\IR>H^A% S.^+.G^)];\++=W^AV=LFG/YIEAO#*^P\,-NP<?=)Y_AH!'3
M?!O7O[9\!06\C9GTYC;-_NCE#^1Q^% CT&@#.UT$Z-<8']W_ -"% '*6\NT@
M9Q3$;=K>*!L(_=*"6'][ZTADL<EK%Y;"&-"P.2%Z>X]* *EW=F08?[XXSZT"
M,HN7G11R2PI@=Y2&<-\5_$@\/^"KF*%\7VH?Z- JGYN?O$8]!G\2* .C\,:+
M'X=\,Z=I,8'^C0A6(&-S]6/XL2?QH ;XJT5/$/A;4M*8 FXA94)&=KCE3^#
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M0I((!QWZ4 9^CW5Q>VSW$Y7!?"!1@8'>@#1H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % %.?3;>XN!/)YAD7[I$A&WZ>E %R@ H *
4"@ H * "@ H * "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g521080dsp03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp03.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MV/\ UPM/_2HU<_XS]?\ VT>*_P!ZGZS_ /2$2ZI_J_"/_85;_P!&&HI?$_\
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MPU=H>L/_ $E')Z/_ ,>F@_\ 8*O?YO776^*I_P!NGL8GXZW^.'Z'3Z5TO/\
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L)A4[V'0GCDCUH4FK6>Q:Q%96M-Z:+5Z(M)&D0(C14!)8A1C)/4TC%MO<_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g521080dsp03b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp03b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( )T ' ,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /8]?\10:%) LUQ:1>:"1]H=USC'3:I]:J$7)M(]#!X*6)3<
M4W;M;]6C&_X6!9?]!#2_^_LO_P ;K3V,NS.W^QZO\DON7_R0H\?V9( O]+_[
M^R__ !NA49-[,'D]1?8E]R_^2.TK$\(Y?Q;:WEQ+:FTUFQTX*&W"ZBC<OTZ;
M@<8]O6M*;BF[JYZV75*<%+GIRGZ-JWW'-_V9K'_0X:)_X"P?_$UKS0_D_%GJ
M>WP__0//_P "E_F*NF:N&&?%^B$9Z?98/_B::E"_P?BQ.OA[?[O/[Y?YGI8Z
M5RGRQR/C.[@M9K03:JECN5L!B!NZ>L;_ -*TIIMNRN>SEE.4XRY:?-_7^*)R
M_P#:UE_T-,/_ 'TG_P CUMR/^7\_\SUOJ]7_ )\/\?\ Y8.75;+< /%$)YZ;
MDY_\EZ:@[_!^?^8GAZEOX#_'_P"6'J@Z5R'R)R_BVUO+B6U-IK-CIP4-N%U%
M&Y?ITW XQ[>M:4W%-W5SULNJ4X*7/3E/T;5ON.;_ +,UC_H<-$_\!8/_ (FM
M>:'\GXL]3V^'_P"@>?\ X%+_ #%73-7##/B_1",]/LL'_P 334H7^#\6)U\/
M;_=Y_?+_ #/2QTKE/ECG?$VSS;;=<S0\-_JY;=,].OF@_I50W>G]?(]/ WM*
MT4_52?\ Z3^I@XA_Z"5W_P"!-C_\36E_)?B>A[W\B^ZI_F"B$,/^)C=_^!-C
M_P#$TT]=E^(/F_D7W5/\ST =*P/G#D_&.D:CJDMH;'2=-OA&K!C>[LKG&-N"
M*UI246[MKT/9RW$T:"DJE24;V^&WXZ,YC_A$]?\ ^A6\._\ C_\ \76WM(?S
M,]7^T<)_S_J?A_D*GA37PZD^%_#H /;?G_T.FJL+_$Q/,,+;^/4_#_(]2'2N
M,^2.=\36;74ML5"_*&^]8/<>G]UABJA9-W/3P-504K_^E*/YIW,'^R)/[L?_
M ((YO_CE:7C_ $_^ >A]8CY_^#(__(@NDN&'RQ_^"2;_ ..4U)7_ .#_ , '
MB%Y_^#(__(GH Z5@?.'&>.;.:ZFLC%HEYJ6U6R;>Z,.SIUX.<_TK6DTF[NWR
MN>[E56,(RYJJAMO&]_Q.1_LB[_Z$S5O_  :'_P")K>\?YE]Q[/UFG_T$P_\
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M_.S_ /BZOECW7XG;['"=X_\ E3_(47_B#(!2_'XV?_Q=-1C?=?B+V.%[Q_\
M*G^1V58GB'%>/+^*RFL1)J5E9[E? N;(W!;ITPIQ6M&+DW97/>RFC*I&=H2E
MMM+E_57./_MRU_Z&/1O_  3-_P#$5T>R?\K^\]KZI4_Y\S_\&+_,<FMVI=1_
MPD6CGGI_8[?_ !%-4G?X7]XGA)I?P9_^#%_F>QCI7"?$'/\ B2]^R26X^SQR
M[@?OV4D^.G]SI^-5!7;/2P5+VB>MO^WE'\S"_MD?\^%O_P"":?\ PK3D?]-'
M?]5_O/\ \&1%&L D#[!;_P#@GG_PIJ#O_P % \-_>?\ X,B=X.E8'SQQ7CR_
MBLIK$2:E96>Y7P+FR-P6Z=,*<5K1BY-V5SWLIHRJ1G:$I;;2Y?U5SC_[<M?^
MACT;_P $S?\ Q%='LG_*_O/:^J5/^?,__!B_S')K=J74?\)%HYYZ?V.W_P 1
M35)W^%_>)X2:7\&?_@Q?YGL8Z5PGQ!@^(;E[>2 ):+/D'EK&2XQT_N#C\:J"
MNV>C@X*:=Y6_[>4?SW,7^T9O^@5'_P""2X_PK3D_JZ.[V$?Y_P#RI !J$V0/
M[*C_ /!+<?X4*&N_XH3HQ_G_ /*D3N*Q/!.2\97DUK-:")K!=RMG[7?-;GMT
MPPS6E./,W_PY[.6THSC+FYO^W8\WZ.QS']K7G_/30O\ P=O_ /%UM[-=G]QZ
MOU:GVG_X+7^0JZM=E@/,T+KVUI__ (NFJ:OU^X'AJ:6T_P#P6O\ (]3'2N0^
M1.6\7-HRRVO]JV=C.=K>6;JY$6.F<9'/:KI\UWR_@>OERQ+4O82DN]E<YOS/
M"'_0)T3_ ,&"_P"%;?O?,]2V8?\ /R?_ ("_\Q5D\([AMTG1,YXQJ"_X4U[6
<^[$UF%OXD_\ P%_YGI@Z5RGRH4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g521080dsp03c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080dsp03c.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M-. ]K=1_(4 :NEZ1I^B6AM=,LXK2W+%_+B7 R>I_04 7: "@ H * "@ H *
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ME8V[VUJL<C@D=AT7V% &.NFZH;"Y@+QH7<OD'F0GU/84Q&II=I+9V:1RL,@
M;5Z+_P#7[TAEV@ H * "@ H * "@ H * "@ H * "@ H * "@"K?03W-NT,,
MJQ!P0Q*Y./;F@ T^V>SLTMW96V< JN./?WH M4 % !0 4 % !0 4 % !0 4
-% !0 4 % !0 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g521080g49g15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080g49g15.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\
M$4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U
M3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A
M2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__
M !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_
MM4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_
MX4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?
M_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^
M?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!<
M/^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O[
M'_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK
M_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !%
M7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[
M^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX
M:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 1
M0%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/
M^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(
M>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\
M$4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U
M3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A
M2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__
M !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_
MM4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_
MX4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?
M_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!</^%(>&O^
M?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O['_\ $4!<
M/^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK_G^U3_O[
M'_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !% 7#_A2'AK
M_G^U3_O['_\ $4!</^%(>&O^?[5/^_L?_P 10%P_X4AX:_Y_M4_[^Q__ !%
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M='<<ERPDWND=M4B"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MR'[0T)B01G)VX?G:#GVJHZ5HI_ROY]B9W<)V_F6WXEF]*GPU\12N-OVSC'_
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M0P6E&:>_]?U]Q[56!04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M75/_  ;+_P#'* #_ (0[XP?\]=4_\&R__'* #_A#OC!_SUU3_P &R_\ QR@
M_P"$.^,'_/75/_!LO_QR@ _X0[XP?\]=4_\ !LO_ ,<H /\ A#OC!_SUU3_P
M;+_\<H /^$.^,'_/75/_  ;+_P#'* #_ (0[XP?\]=4_\&R__'* #_A#OC!_
MSUU3_P &R_\ QR@ _P"$.^,'_/75/_!LO_QR@ _X0[XP?\]=4_\ !LO_ ,<H
M /\ A#OC!_SUU3_P;+_\<H /^$.^,'_/75/_  ;+_P#'* #_ (0[XP?\]=4_
M\&R__'* #_A#OC!_SUU3_P &R_\ QR@ _P"$.^,'_/75/_!LO_QR@ _X0[XP
M?\]=4_\ !LO_ ,<H /\ A#OC!_SUU3_P;+_\<H /^$.^,'_/75/_  ;+_P#'
M* #_ (0[XP?\]=4_\&R__'* #_A#OC!_SUU3_P &R_\ QR@ _P"$.^,'_/75
M/_!LO_QR@ _X0[XP?\]=4_\ !LO_ ,<H /\ A#OC!_SUU3_P;+_\<H /^$.^
M,'_/75/_  ;+_P#'* #_ (0[XP?\]=4_\&R__'* #_A#OC!_SUU3_P &R_\
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M!_SUU3_P;+_\<H /^$.^,'_/75/_  ;+_P#'* #_ (0[XP?\]=4_\&R__'*
M#_A#OC!_SUU3_P &R_\ QR@ _P"$.^,'_/75/_!LO_QR@ _X0[XP?\]=4_\
M!LO_ ,<H /\ A#OC!_SUU3_P;+_\<H /^$.^,'_/75/_  ;+_P#'* #_ (0[
MXP?\]=4_\&R__'* #_A#OC!_SUU3_P &R_\ QR@ _P"$.^,'_/75/_!LO_QR
M@ _X0[XP?\]=4_\ !LO_ ,<H /\ A#OC!_SUU3_P;+_\<H /^$.^,'_/75/_
M  ;+_P#'* #_ (0[XP?\]=4_\&R__'* #_A#OC!_SUU3_P &R_\ QR@ _P"$
M.^,'_/75/_!LO_QR@ _X0[XP?\]=4_\ !LO_ ,<H /\ A#OC!_SUU3_P;+_\
M<H /^$.^,'_/75/_  ;+_P#'* #_ (0[XP?\]=4_\&R__'* #_A#OC!_SUU3
M_P &R_\ QR@ _P"$.^,'_/75/_!LO_QR@ _X0[XP?\]=4_\ !LO_ ,<H /\
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M75/_  ;+_P#'* -+P]X4^*EMXETJ?49-1-C'=Q/<!]45U\L."V5\PY&,\8H
M]\H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
(4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g521080page_040.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080page_040.jpg
M_]C_X0\T17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-#HP-#HQ,B Q,3HU,CHU,P   Z !
M  ,    !  $  * "  0    !    Q* #  0    !    1P         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M)*>_7#=-/7^L]=ZG]8^COPV4M>>EXCLRNRPFC'.^ZW'?C74-]+)S'O?[]_\
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M       0QS+YC9O=M;%;W9;7B@@##CA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !  (!
M+     $  CA"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #@0    8              $<   #$    )@ P #$ 5 !)
M %4 0@!? $$ 4@!# $$ 7P!B &D ;P!P &@ 80!R &T 80!? %  <@!O '@
M>0!? #  -  M #  -  M #$ -  M #(    !
M  $              ,0   !'                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   !'     %)G:'1L;VYG    Q     9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    1P    !29VAT;&]N9P   ,0    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!0
M  0    ".$))300,      X:     0   *     Z   !X   ;,    W^ !@
M ?_8_^T #$%D;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1"  Z * # 2(
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M9^C_ .,5KZ@Y_1+.@8G3.EV[K<"BL9=#FN98RU\ON]6NP#Z>1ZWT?8DIXO\
MQ@8GUBZ7U'IWUFSG8EE]=C*V.Q&65LWT%V7CMO;=;<ZUUS/M-/\ Q:]4PLNC
M.PZ,W'.ZC)K9=43H2U[18S_HN7)_XR\_HKNA9'2,J\-ZE8QN1@X[6.LL+V.W
M5.:QC7;66.JLI>_]SU%D_P"+_P"NG3^F])KZ-UIUF&['L+,.^ZNP5OK>38RM
MUSF^RRESGU_I/3J]+T4E/__1]+R^G8N60ZUI%@$"QAAT?N_RO[2KCH6*.+;O
M\X?^06DDDISCT/&/^%N_SF]O["3.A837;GE]H_=>[VG^L&ANY:*22E@   !
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  ( !# %, -@    $ .$))300&
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M0@               0  ]M8  0    #3+4A0("
M                                         !%C<')T   !4    #-D
M97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&
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M+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                6%E:(
M /-1  $    !%LQ865H@                     %A96B        !OH@
M./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "V
MSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                              !D97-C         "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-2
M1T(                             9&5S8P         L4F5F97)E;F-E
M(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                                 '9I97<      !.D_@ 47RX $,\4
M  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M   !                         H\    "<VEG(     !#4E0@8W5R=@
M      0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D
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MP  1" !' ,0# 1$  A$! Q$!_]T !  9_\0!H@    8" P$
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MV:CWKMK=^9VWM22JP5;#25%5N7;TDM338X9*++9*FI:]Z>ABKW96D5W1PMG
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MO>Z-A[ZW)G-A[<@W#B\QM3%8W)_PW<.V<MMK[S;E:13XW,8>#*T]-43XJ4!
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$W7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g521080snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g521080snap1.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M3Z'X:273/"\3>7>ZDZE9)5[JOID=NOKC.* /8+6VBLK2&U@!$4*+&@))(4#
MY/6@"6@ H * &LZH0&8 DX&3UH X[4?B;H6F%I)[75C9)]Z]73I3 .<??QS]
M1Q0!U&F:I8ZSIL&H:;<I<VDZ[HY4.01_GM0!;H * "@ H * "@ H 9+-%;IO
MFE2-,@;G8 9)P!S0 ^@ H :[K&C.[!449+$X 'K0!Y%XP\7?\)&L-I;O=)H5
MS(8H8;3BZUEAU6/^Y /XI#U[>X!KZ7;V7@2%-4UL(VNWL0M;/3;%=WE1CE;>
M%>_/+.>">210!S\5KK7Q1UC-S<+'IMK(0\MN=T%L>Z0D\338X,OW4R=HR<T
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M2!C):P(Q$<(4#(X&3CJ3S0!T0\7^(_%+>3X1T1[6T;@ZKJJ&.,#UCB^\_MG
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C?)H [Z"WAM($@MX4AA085(U"JH]@.E $E !0 4 % !0!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
